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ABSTRACT
BIOPHYSICAL UNDERSTANDING OF NOVEL SYNTHETIC
AMYLOID-β (Aβ) PRIONS IN ALZHEIMER`S DISEASE.
by Amit Kumar
August 2013
Oligomers of amyloid-β (Aβ) peptide are the primary toxic agents that play a
pivotal role in the pathogenesis of Alzheimer’s disease (AD). Oligomers are the
intermediates formed during the Aβ aggregation process leading up to insoluble fibrils. It
is important to know that oligomers can also be formed via pathways that do not lead to
fibril formation. Such ‘off-pathway’ oligomers would have significantly longer half-lives
than the ‘on-pathway’ ones, which may result in prolonged toxicity to neuronal cells.
Furthermore, neither the mechanism of neurotoxicity nor the potential mechanisms of
propagation and proliferation to neighboring cells are well understood. Moreover, recent
in vivo studies on transgenic animal models have implicated a prion-like mechanism
involved in the propagation of toxic oligomeric seeds. Interfaces generated by lipids,
fatty acids and other surfactants are well known to affect A aggregation, especially in
inducing alternate pathways. In this study, the effect of saturated non-esterified fatty
acids (NEFAs) on the rate of A aggregation was studied. We have observed that
NEFAs were able to induce an alternate pathway of aggregation, which was depended on
NEFA concentrations. More importantly, in a narrow concentration range, NEFAs
induced the formation of 12-18mers (Large Fatty Acid-derived Oligomers; LFAOs),
which were isolable by size exclusion chromatography (SEC). We discovered that
LFAOs can behave like prions, undergoing self-propagation, by quantitatively converting
ii

monomeric Aβ into toxic LFAO assemblies in a template-assisted manner. We further
analyzed the prion-like behavior of LFAOs by the ‘protein misfolding via cyclic
amplification’ (PMCA) assay, as was done for prions. Together, our findings indicate
that LFAOs are unique Aβ prions and support the developing hypothesis that a common,
prion-type mechanism of infectivity could be an underlying conserved mechanism among
many neurodegenerative diseases.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder,
which is mostly prevalent in the people above the age of 60.4 AD is the most common
among all neurodegenerative disorders and other forms of dementia. According to recent
epidemiological data, it is estimated that around 4.5-5 million Americans are affected by
AD, and this figure is predicted to increase to 11-16 million by 2050.5

Figure 1. APP Cleavage and Aβ Generation. A) Bright-field immunohistochemistry
showing deposits of plaques (dotted arrow) and neurofibrillary tangles (solid arrow) in
the AD brain section.1 B) Schematic representation of extracellular release of A after
APP cleavage.3 C) APP (amyloid precursor protein) amino acid sequence with α-, βand γ- secretases cleavage sites. The γ secretase can cleave at multiple sites to generate
Aβ ranging from 39-43 amino acids.
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The deposition of A peptide aggregates primarily in the cortical and
hippocampal regions of the brain is mainly responsible for the cognitive decline and
memory loss that occur in AD. The two classical hallmarks of the AD brain are neuritic
plaques and neurofibillary tangles (Figure 1A). Neuritic plaques are large, proteinacious,
extracellular deposits, mainly composed of 40- and 42-amino acid long peptides (A 40
and Aβ42, respectively) collectively called amyloid- (A ) peptides. Neurofibillary
tangles are intracellular inclusions consisting of the aggregated form of hyperphosphorylated Tau protein.4, 6-8 Although both A and Tau are known to be involved in
the pathogenesis of AD, A aggregation is largely believed to be the primary neurotoxic
event in AD pathogenesis.
A peptides are generated by the sequential cleavage of a ubiquitously expressed,
transmembrane protein called the amyloid precursor protein (APP; 770 amino acids) by
aspartyl proteases - and - secretase (Figure 1B). The initial cleavage of APP on the Nterminal side by - secretase generates a large ectodomain and retains a 99-residue
COOH-terminal fragment (CTF) within its transmembrane domain, which is then cleaved
by - secretase, which releases the intracellular domain of APP into the cytoplasm and
A in the lumen (Figure 1B).6, 8,9 The - secretase is a multi-subunit protease complex
that consists of presenilin-1 or presenilin-2, nicastrin, APH-1 (anterior pharynx-defective
1), and PEN-2 (presenilin enhancer 2).10 The -secretase complex has a wide specificity
and can cleave anywhere between the 711th and 714th residues in APP, corresponding to
A 39 to 43 versions, among which A 40 and Aβ42 are the predominant forms (Figure
1C). Alternatively, instead of -secretase cleavage, another protease called α-secretase
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that belongs to the A Disintegrin And Metalloproteinase (ADAM) family of proteases
can cleave APP within the A sequence (Figure 1C). This releases a soluble N-terminal
domain of APP called P3 containing 83 amino acids which possesses neurotrophic and
neuroprotective properties.6
AD is largely an idiopathic disorder, but a small percentage is familial, with
mutations in specific genes that can lead to excessive deposition of A in brain areas
linked to memory and cognitive function.2 Genetic mutations in APP that lie outside the
A sequence (see Figure 2) give rise to early–onset familial AD (FAD).2 These
mutations can lead to an increased production of the longer and more amyloidogenic
form, A 42.

Figure 2. APP Mutations Genetically Linked to Familial Alzheimer’s Disease (FAD) or
Related Disorders. The sequence within APP that contains the Aß and transmembrane
(TM) regions is expanded. The underlined residues represent the Aß1–42 peptide. The
vertical dashed lines indicate the location of the TM domain. The letters below the
wild-type sequence indicate the currently known missense mutations identified in
certain patients with familial AD and/or hereditary cerebral hemorrhage with
amyloidosis. Three-digit numbers refer to the codon number according to the ßAPP770
isoform.2
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A Aggregation
Once generated, Aβ peptides can undergo aggregation, which is a nucleationdependent process analogous to crystal growth. This process is characterized by the
presence of a ‘lag-phase’, during which prerequisite conformational changes take place,
followed by growth-phase towards fibril formation in a sigmoidal pattern (Figure 3).11, 12,
13

During aggregation, the natively unstructured (random coil) monomeric A undergoes

conformational changes that result in a cross- -sheet structure observed in A fibrils.
The lag-phase can be eliminated by adding small amounts of pre-formed aggregates to
monomers in a process called ‘seeding’.14
Oligomers in A Aggregation
Previously, it was believed that A fibrils are mainly responsible for memory
impairment and cognitive decline in AD, which led to the formulation of the ‘classical
amyloid hypothesis’.15, 16 However this has been widely contested over the years after it
became evident that cognitive decline occurred well before emergence of amyloid
plaques in transgenic AD mouse brains.17-22 Several of such observations have resulted
in a relatively new amyloid hypothesis that low molecular weight ‘soluble oligomers’
between ~2-60mers are the primary toxic agents in AD. Consequently, several soluble,
low-molecular weight oligomers were identified both in vivo as well as in vitro, which
led to the isolation of many intermediates, including protofibrils (Figure 3).12, 23-27 Low
levels of endogenous, soluble A aggregates present considerable challenges in their
identification and characterization; however, several species have been detected in the
extracts of human AD brains that run as discrete bands on SDS-PAGE immunoblots.19, 20,
28, 29

The molecular masses of these bands represent multimers of ~4 kDa A monomers
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and range from 2-10mers, and they are collectively called low-molecualr weight, soluble
oligomers. It has also been shown that these oligomers are not the broken fragments of
larger aggregates that may be formed by SDS during SDS-PAGE analysis.20, 28 More
recently, Shankar and coworkers fractionated the soluble extracts from human
postmortem AD brains by superdex-75 size exclusion chromatography (SEC) and
showed that dimeric A caused memory impairment and synaptic dysfunction.29

Figure 3. Schematic Representation of A Aggregation ‘On-pathway’. (Inset): The
sigmoidal growth curve of the A aggregation showing lag-phase and post- nucleation
phase.
This hypothesis was further confirmed by the identification of naturally secreted
soluble oligomers that inhibit hippocampal long- term potentiation (LTP) in an AD
transgenic mouse model and caused impaired cognitive decline.30,31 LTP is a measure of
synaptic plasticity and its inhibition leads to synaptic dysfunction and cognitive decline.
Lesńe and coworkers reported that 3-9 month old Tg2576 mice generated a series of
oligomeric species with molecular weights corresponding to 6, 9, 12, and 15mers. They
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fractionated different species using a Superdex-75 SEC column and determined that a
56kDa (12mer) species, termed as A *56, showed good correlation with the spatial
memory deficits in Tg2576 mice.28 This was the first successful attempt to fractionate
endogenous oligomers. They claimed that the 12mers were exclusively responsible for
the early synaptic dysfunction and cognitive decline observed prior to the emergence of
plaques in AD mice.28 The soluble oligomers are thought to induce memory loss via
synaptic dysfunction prior to cell death.32
In another independent work, Townsend and colleagues showed A trimers to be
more potent in disrupting LTP than dimmers.20 They have identified a conditioned
medium of the APP V717F-expressing Chinese hamster ovary (CHO) cell lines that form
low-number oligomers intracellularly. These naturally secreted soluble oligomers at
picomolar concentrations could disrupt hippocampal LTP in the mammalian
hippocampus.20 Podlisnky and coworkers claimed the detection of small amounts of
SDS-stable A oligomers in the culture media of CHO cells expressing endogenous
amyloid beta-protein precursor genes.33 These oligomers were primarily identified as
dimers and trimers by immunoprecipitation with a panel of A antibodies which included
rabbit antisera such as R1280 R1282 and R1963, as well as by electrophoretic comigration with synthetic A oligomers and amino acid sequencing. Selkoe and coworkers developed protocols for separating secreted oligomers from cell culture by SEC
under non-denaturing conditions.20, 34, 35 They fractionated A monomers and oligomers
generated and secreted by conditioned CHO cell medium by SEC and tested them
separately on mouse hippocampal slices. They found that trimers are more potent in
inhibiting LTP as compared to dimers, suggesting the existence of a level of molecular
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specificity in the interaction of A oligomers with neuronal targets. Most recently, Glabe
and coworkers shown that fibrillar and prefibrillar oligomers may play a key role in
preceding dementia in AD.36
Due to their increasing significance in AD pathology, it is becoming imperative to
explore and understand the properties of low molecular weight, soluble A oligomers.
Endogenous Aβ oligomers are difficult to isolate and are present in extremely low
amounts in physiological samples, making biophysical analyses a considerable challenge.
Hence, many groups have focused on generating in vitro oligomers that can mimic
endogenous ones.28, 29, 33, 36-39 Increasing interest in role of smaller oligomers in AD led
to the generation of small diffusible Aβ42 oligomers, referred as A -derived diffusible
ligands (ADDLs), which are mostly comprised of Aβ42 4-5mers.38 The 4-5mers were
initially generated by co-incubating Aβ42 with a protein called clusterin and later by
simply incubating Aβ42 in DMEM/F-12 hippocampal cell culture medium.37, 38 ADDLs
were toxic to neuronal cells and inhibited LTP in rats.38 Later, Chromy and coworkers
were successfully able to isolate and characterize these ADDLs using SEC and atomic
force microscopy (AFM). Results from these experiments indicated that they are fairly
homogenous with an average height of ~ 5 nm in AFM.40 Additionally, fairly
homogenous and soluble globular oligomers named ‘globulomers’ were generated by
Barghorn and coworkers, which completely blocked LTP in rat hippocampal slices. In
order to generate these, they incubated the Aβ42 peptide in 7 mM SDS initially, diluted
the solution to 1.8 mM SDS and dialyzed to remove SDS molecules, yielding
globulomers in MW range of 38-50 kDa.37 Later, they showed that these globulomers are
formed via a pathway that was different from the fibril formation pathway, termed as ‘off
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pathway.41 Despite reasonable progress on in vitro oligomer generation, detailed
mechanistic and biophysical information is still lacking, partly due to the difficulties
involved in their generation itself.
Amyloid Polymorphism and Structural Classification of Oligomers
Recent studies have shown that amyloid fibrils are polymorphic, that a single
polypeptide can fold into multiple amyloid conformations, and factors which can affect
the rate limiting nucleation step can dictate the pathway of A aggregation.42 This
feature was ﬁrst noted with mammalian and yeast prion proteins where it was observed
that a single polypeptide can misfold into multiple amyloid conformations.43 Recently,
two types of amyloid ﬁbrils were formed by A 40 following aggregation under mildly
agitated or quiescent conditions; chemical shift and line-width data from solid-state NMR
for 33 of the 40 residues indicated different underlying structures.44, 45 They also showed
that different fibril morphologies may have different underlying molecular structures,
which was confirmed by AFM and electron microscopy (EM), that the predominant
structure can be controlled by subtle variations in fibril growth conditions, and that both
morphology and molecular structure are self-propagating when fibrils grow from
preformed seeds.44, 45
Furthermore, Glabe and coworkers classified the soluble oligomers into three
structurally distinct classes based on their conformation as well as their ability to be
recognized by certain conformation-specific antibodies. These classes of oligomers are
prefibrillar oligomers (PFO), fibrillar oligomers (FO) and annular protofibrils (APFs),
which are recognized by A11, OC and PF specific antibodies respectively.36 FOs are
small fibrillar fragments which can act as seeds for fibril formation and
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elongate/aggregate mainly by monomer addition. In contrast, PFOs are early
intermediates of aggregation, specifically recognized by the oligomer-specific A11
antibody. PFOs can align themselves to form protofibrils, which undergo a conformation
change to finally form fibrils. Moreover, the N-terminal 6E10 epitope of PFOs has
displayed polymorphism in acidic pH, which is completely unobserved at neutral pH.46
On the other hand, APFs are a completely new and distinct class of oligomers, mainly
characterized by pore-like structure and PF specific antibody. It has been shown that
PFOs act as a precursor for APF formation, which are formed by circular arrangement of
PFO subunits.47 These pore-like structure lead to membrane permeabilization and
disruption of iron homeostasis causing cell death, a mechanism similar to bacterial poreforming toxins.47
It is abundantly clear that structural variability in A can arise from the conditions
in which A is aggregated. Based on Glabe’s oligomer classification, several researchers
attempted to determine whether the known in vitro and in vivo oligomers belong to the
fibrillar or prefibrillar class of oligomers. It has been observed that the in vitro generated
oligomers ADDLs and globulomers are not detected by either PFO- or FO- specific
antibodies. Interestingly, anti-ADDL and anti-globulomer specific antibodies have
shown very high reactivity with A plaque deposits, suggesting that they may have an
epitope similar to FOs, fibril type oligomers.32, 48, 49 In contrast, in vivo generated A *56
isolated by Lesné and coworkers belongs to the prefibrillar oligomer class because they
have shown high reactivity towards the A11 antibody on immunoblots.28
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Interfacial Aggregation and Off-pathway Oligomers
A aggregation is a nucleation dependent process as mentioned earlier, and this
aggregation process can be affected by environmental factors such as pH, ionic strength,
temperature, concentration etc. In addition, the amphipathic nature of A peptide
induces preferential aggregation at hydrophilic/hydrophobic interfaces, indicating that
interfaces may play a significant role in the A aggregation.50, 51 Both physiological and
non-physiological interfaces are well-known to affect to A aggregation. Nichols and
coworkers have unambiguously demonstrated this interfacial phenomenon by showing
that A 40 aggregation was accelerated by both polar-non polar interfaces as well as by
microdroplets of hexafluoro-2-propanol (HFIP). 52, 53
Physiological interfaces such as those formed by biological membranes and
anionic lipids are known to play important role in aggregation and oligomerization.54, 55
Lipid rafts enriched with gangliosides such as GM1, GD1a, GD1b, and GT1b, along with
cholesterol and sphingomyelins, are abundant in the brain and are known to affect A
fibrillogenesis.56-58 These rafts are found largely but not exclusively in cell membrane
domains known as caveolae.55 Importantly, the , and - secretases that generate A
peptide from APP, as well as the A peptides themselves, are concentrated in lipid rafts,
suggesting that lipids may play pivotal role in A amyloidogenesis.56-58 Moreover, lipids
and lipid metabolites present in amyloid deposits have the potential to affect several areas
of amyloid metabolism, including the formation, stability, morphology, and toxicity of
fibrils.59-61 Many studies have focused on lipid bilayers and membrane surfaces where
the effect of lipids on A fibril formation is variable and depends on the protein/lipid
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ratio and the degree of membrane penetration.62 But generally it is accepted that A
fibril formation is enhanced by the presence of a negatively charged lipid surface.59, 61, 62
Peroxidized lipids and their derivatives such as 4-hydroxynonenal are involved in
promoting A deposition, linking oxidative stress to amyloid deposition.63 It has also
been shown that biological lipids present in the brain can revert inert A plaques or
fibrils into highly toxic oligomers, which causes memory deficits in mice.64 The
interaction of sialic acid with A can also promote toxic oligomer formation by inducing
peptide conformational change.65 Furthermore, it has also been observed that neuronal
receptors that bind to A oligomers are mainly embedded in lipid rafts, promoting
toxicity.66
In vitro interactions of A with glycosphingolipids, such as GM1ganglioside, in
which micelles and reconstituted liposomes act as rafts to promote A binding and sheet structure have been reported.67-69 Biological membranes can also promote the
aggregation of A because of the presence of abundant amounts of phospholipids with
polar head groups that can provide an anionic micellar interface. But the interaction of
A with these anionic phospholipids/sphingolipid vesicles is limited to polar head groups
without penetration of A into bilayer.70, 71 The rate of A aggregation at an anionic
micellar interface can be compared to the rate of aggregation at polar-nonpolar interface
using a detergent, sodium dodecyl sulfate (SDS), Although SDS-PAGE analysis is most
commonly used as a technique to identify endogenous, soluble A oligomers and SDS is
considered as a denaturant that can destroy native protein structure, in low concentrations
it can provide an anionic, micellar interface that has been shown to increase A
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aggregation.72 In contrast, SDS concentrations well above the critical micelle
concentration (CMC) restrict the peptide in a α-helical structural conformation that does
not aggregate.73, 74 Moreover, Rangachari and coworkers have concluded that Aβ42
rapidly forms oligomers as opposed to protofibrils in concentrations below the CMC of
SDS by distinct pathway that they called the “off pathway”. These observations
indicated that the aggregation pathway depends upon the SDS: A ratio.73-76
These published reports indicate that interfaces generated by lipids can alter the
A aggregation pathway and, more importantly, can generate toxic oligomers as offpathway products and play a pivotal role in promoting the exclusive formation of
neurotoxic oligomers.
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Prion-type Propagation Mechanism –
Conserved Among Neurodegenerative Diseases?
The process of self-propagation is well known among prion diseases, which are
also called ‘spongiform encephalopathies’. The most common ones are CreutzfeldtJakob disease (CJD) and Kuru disease in humans as well as Bovine spongiform
encephalopathy (BSE) and scrapie in animals. In prion disease, the normal prion protein
in its non-toxic, cellular form, PrPC, converts to a misfolded and infectious scrapie form,
PrPSc. PrPSc is responsible for the propagation of the disease. Prion propagation is a
continuous process, in which newly formed PrPSc act as template for further initiating the
misfolding to continue prion propagation.77, 78 This ‘protein only’ hypothesis of prion
infectivity was first introduced by Griffith in 1967.79 It is now believed that a similar
protein corruptive mechanism may be also involved in the pathophysiology of other
neurodegenerative disorders like Parkinson’s disease (PD), frontotemporal lobar
dementia (FTLD) and amyotrophic lateral sclerosis (ALS). Desplats and coworkers have
shown that α-synuclein involved in PD can migrate and infect neighboring neurons and
form lewy bodies, suggesting a prion like propagation mechanism.80 More recently,
Christian and coworkers have shown that extracellular α-synuclein can enter cells by
endocytosis and act as ‘seed’ to promote the aggregation of intracellular α-synuclein in
mouse models, further indicating the involvement of prion like corruptive propagation.81
Similar types of behavior have been also reported for the mutant of superoxide dismutase
(SOD1) and TDP43 protein involved in ALS and FTLD, respectively.82, 83, 84 In the AD
field, self-propagation of oligomers is a fairly new and underexplored concept, which
requires a great deal more understanding and verification. So far, only a few reports have

14

been published showing that in vitro generated oligomers can undergo replication to
generate a similar type of oligomers from monomers on seeding. FOs and PFOs have
been shown to undergo self-replication, generating similar type of oligomers from
monomer.85, 86
Several in vivo studies demonstrate that the self-propagation behavior of A
amyloids is similar to prions. Jucker and coworkers have shown that brain extract
containing A from AD patients or -amyloid precursor protein (APP) transgenic mice
produce cerebral -amyloidosis and other related pathologies in the transgenic APP
mouse model in a time and concentration dependent manner following exogenous
induction.87 Later on, they have also shown that these exogenous seed have similar
properties to the PrPSc form of prion protein.88 More recently, Stoehr and coworker have
shown that A aggregates, whether purified from brain extract or formed from synthetic
A , act as prions by inducing widespread cerebral -amyloidosis.89 These findings
clearly indicate and further support the current hypothesis that ‘template-assisted
corruptive’ protein propagation could be the common mechanism of disease progression
and toxicity in all of these neurological disorders. Unfortunately, research so far has been
very segregated, failing to give a clear picture of disease pathology and provide a
perspective on clinical significance/implications.
Despite the emerging wealth of information regarding soluble oligomers, several
molecular level questions still remain that need to be answered. Some of these are:
1. Are there any similarities/dissimilarities between off- and on-pathway
intermediates?
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2. Is there an underlying mechanism of self propagation and toxicity that is
conserved among all neurodegenerative diseases?
3. What is the structure of pathogenic oligomeric seed?
4. Is propagation specific to off-pathway intermediates?
5. Is propagation the property of a specific conformation of seed? If so, what is the
optimum threshold concentration of ‘seed’ required to initiate propagation?
6. What external parameters can affect prion-type propagation?
My current research efforts will be focused on understanding some of these
questions, which will provide insights into the mechanism of AD pathology. My findings
may also open doors for the development of new diagnostic strategies and help to
counteract disease progression through presymptomatic detection and prevention.
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CHAPTER II
MATERIALS AND METHODS
Wild type (WT) and Dansyl (Dan) Aβ42 were synthesized by the Peptide
Synthesis Facility at the Mayo Clinic (Rochester, MN) using routine Fmoc chemistry.
MALDI-TOF mass spectrometry revealed >90% purity of both peptides. SDS and
thioflavin-T (ThT) were procured from Sigma (St. Louis, MO). All saturated fatty acids
were purchased as sodium salts from NuCheck Prep Inc (Elysian, MN). Monoclonal
Ab9/Ab5 antibody specific for Aβ1-16 was supplied by the Mayo Clinic (Rochester,
MN). The 1 X 30-cm superdex-75 HR 10/30 SEC column was purchased from GE Life
Sciences. Gel electrophoresis and blotting instruments and buffers were procured from
Bio-Rad Laboratories, Inc. All other chemicals were obtained from VWR Inc.
Preparation of Aβ42 Monomers
Lyophilized stocks of synthetic Aβ42 were stored at -20 C, desiccated. Briefly,
1.5- 2 mg of peptide was dissolved in 0.5 ml of 35 mM NaOH and stored for 15 minutes
at room temperature prior to size exclusion chromatography (SEC) on a 1

30 cm

Superdex-75 HR 10/30 column (GE Life Sciences) attached to an AKTA FPLC system
(GE Healthcare, Buckinghamshire) to remove any preformed aggregates as previously
reported.90 The column was pre-equilibrated in 20 mM Tris-HCl buffer (pH 8.0) at 25 C
and was run at a flow rate of 0.5 ml/min. One minute fractions were collected.
Concentrations of A were determined by UV-Vis spectrometry on a Cary 50
spectrophotometer (Varian Inc) using a molar extinction coefficient of 1450 cm-1 M-1 at
276 nm (www.expasy.org), corresponding to the single tyrosine residue in A 42. Peptide
integrity after SEC was again confirmed by MALDI-TOF mass spectrometry. Which
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shows a monoisotopic molecular mass of 4516.31 Da in a good agreement with a
calculated mass of 4513.13 Da. Monomeric Aβ42 fractions were stored at 4 oC and used
within 2 to 5 days of SEC purification in all experiments to avoid any preformed
aggregates in our reactions.
Aβ Aggregation Reactions
All reactions and measurements were made at room temperature unless otherwise
noted. Reactions were initiated in siliconized Eppendorf tubes by incubating appropriate
concentrations of freshly purified Aβ42 monomer in buffer without agitation.
Aggregation kinetic parameters were obtained by monitoring the reaction with ThT and
fitting fluorescence data points to the sigmoidal curve in Eq. 1 using Origin 7.0.91
Eq. 1

In this equation t is time, a and b are fixed parameters, and t0.5 is the time to reach halfmaximal ThT fluorescence. Data points were unweighted. Lag times were equal to t0.5 −
2b for each fitted curve.
Measurement of Critical Micelle Concentration (CMC)
CMCs of fatty acids were determined using N-phenyl-1-naphthylamine (NPN)
from Sigma (St. Louis, MO) as a fluorescent probe. Fluorescence measurements of NPN
in the presence of fatty acids were acquired at the excitation wavelength of 340 nm while
scanning emission wavelengths ranging from 400-500 nm on a Cary Eclipse fluorescence
spectrometer (Varian Inc.). Fatty acid mixtures contained 0.5-170 mM fatty acid along
with 50 mM NaCl in 10 mM Tris buffer, pH 8.0. NPN was added to a total concentration
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of 1.5 µM and the solution was incubated for 30 minutes at 37 oC. The data points were
fitted to obtain a linear curve using Origin 7.0.
Seeding Experiments
Monomeric Aβ42 (25 M) was incubated alone or with different concentration of
fatty acids in buffer containing 50 mM NaCl and 20 mM Tris pH 8.0. After 48 hours,
10% (m/v) seed of the incubated sample were withdrawn and mixed with fresh
monomeric Aβ42 (25 M) and incubated at 37 C under quiescent conditions along with
a control without seed. The rate of Aβ42 aggregation was monitored using the ThT
assay.
Gn-HCl Denaturation Experiments
The thermodynamic stability of oligomers formed in the presence of fatty acids
was determined by guanidine-HCl (GnHCl) denaturation. Aβ42 (25 M) samples in the
presence of specific concentrations of fatty acids (to generate 12-18mers or 4-5mers)
were incubated at 37 C. Aliquots of the samples were taken after 48 hours of
incubation, and tyrosine intrinsic fluorescence was measured using λex 276 nm and
scanning the emission spectrum (λem) between 300-400 nm with an excitation/emission
slit widths of 10/10 nm on a Cary Eclipse fluorescence spectrometer (Varian Inc). The
sample was then subjected to denaturation by titrating with 6 M GnHCl within the
fluorescence cuvette, at room temperature. The scans were averaged three times to
minimize error. Control spectra were measured by adding buffer without fatty acids to
buffered 25 M Aβ42 using the same volumes of GnHCl, which were subtracted from
the sample spectra. The area under the curve of the blank-corrected spectra was plotted
against the GnHCl concentration. The data were then normalized against the lowest and
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highest fluorescence intensity for the given fatty acid concentration. Three such blankcorrected spectra were averaged and are represented here. The resulting curve is fitted
using the following Boltzman equation: 92
Eq. 2
Where, A1 and A2 are constants, C is the concentration of the denaturant and CM is the
mid-point of the curve, which is considered to be the concentration of melting. The data
was processed using Origin 7.0.
Preparation and Isolation of LFAOs
Freshly purified Aβ42 (50 μM) was incubated with 50 mM NaCl and 5 mM C12
fatty acid at 37 C for 48 hours. After 48 hours, the sample was spun at 19,000 x g for 20
minutes, and the supernatant was subjected to SEC; the peaks near the void volume (Vo)
fractions were collected. Concentrations of collected fractions were determined by UV
absorbance with a molar extinction coefficient of 1450 cm-1M-1 at 276 nm. All isolated
LFAO fractions were stored at 4 oC and used within 2-4 days after SEC isolation in all
experiments.
Agitation Experiments with Hexane-buffer and Chloroform-buffer Interfaces
To freshly purified 2 μM LFAO or Aβ42 monomer (control) in 20 mM Tris, pH
8.0, 5% (v/v) hexane (ρ = 0.6548 g/ml) or chloroform (ρ = 1.483 g/ml) were added
independently and mixed vigorously using a vortex mixer (VWR Inc) for 1 minute of
agitation followed by 5 minutes rest. After eight cycles of agitation (~ 1 hour), the
samples were then dialyzed against 20 mM Tris-HCl (pH 8.0) at 25 C using a 2-kDaMWCO Slide-A-Lyzer G2 dialysis cassette (Thermo Scientific) for 23 hours. Afterward,
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the dialyzed samples were subjected to immunoblotting, dynamic light scattering (DLS)
and atomic force microscopy (AFM) analyses.
Suspension Experiment with Chloroform-buffer Interface
The suspension method reported previously was followed in our experiments.93
Freshly purified 2 μM LFAO or Aβ42 monomer (control) (0.3 mL) was suspended on top
of 100% chloroform solution (0.3 mL) in a 1.5 mL siliconized Eppendorf tube without
mixing. The samples were kept at 25 C for 24 hours without any disturbance. After 24
hours, the samples were removed just above the interface, without disturbing the
interface. The samples from both reactions were subjected to immunoblotting, DLS, and
AFM analyses.
LFAO Propagation Experiment
Monomeric Aβ42 (20 μM) was incubated alone or with 2% (0.4 μM) LFAO seed
in 20 mM Tris pH 8.0 at 25 C for 72 hours. Aliquots of the samples were removed at 0,
24, 48 and 72 hours and then subjected to immunoblotting and AFM after spinning at
19,000 x g for 20 minutes. The 0.4 μM LFAO seeds alone were used as a control.
Similarly, for SEC isolation of replicated LFAO, 50 μM Aβ42 monomer was incubated
with 1 μM LFAO under the same conditions, keeping the A 42: LFAO ratio the same.
Aliquots of samples were removed at 0, 24, 48 and 72 hours and subjected to SEC on a
Superdex-75 HR 10/30 column after spinning at 19000 x g for 20 minutes to remove
fibrils. Fraction 17 from each SEC fractionation at 0, 24, 48 and 72 hours was subjected
to immunoblotting and circular dichroism (CD).
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LFAO propagation experiment with Dansyl-Aβ42monomer
The above experiment was repeated with Dansyl-Aβ42 (Dan-A 42) monomer,
which was purified similarly to wild-type Aβ42, as mentioned above. Freshly purified 50
μM Dan-Aβ42 monomer was incubated with 1 μM LFAO under the same conditions as
mentioned above. Aliquots of samples were removed after 72 hours and subjected to
SEC on a Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes to
remove fibrils. Fractions 17 and 18 from the SEC fractionation were subjected to
immunoblotting and emission fluorescence spectroscopy using a Cary Eclipse
fluorescence spectrometer (Varian Inc.) in scan mode. Dansyl emission was monitored at
450 nm after exciting at 350 nm using 10-nm slits.
Amplification of LFAOs
For Cycle-1, monomeric Aβ42 (50 μM) was incubated with 2% (1 μM) LFAO
seed in 20 mM Tris pH 8.0 at 25 C for 72 hours. After 72 hours, the sample was
centrifuged at 19,000 x g for 20 minutes to remove any fibrils, and the supernatant was
loaded on a Superdex-75 HR 10/30 SEC column to isolate R-LFAOs. Fractions 16 and
17 after SEC fractionation were collected and subjected to immunoblotting to confirm the
presence of R-LFAOs. For Cycle-2, 50% v/v R-LFAOs (Fraction 16) were used as seed
and incubated with 50 μM monomeric Aβ42 for 96 hours at room temperature. After 96
hours, the supernatant was subjected to SEC after spinning at 19,000 x g for 20 minutes
to remove fibrils. Fractions 16 and 17 were collected. For Cycle-3, 50% v/v R-LFAOs
from Cycle-2 (Fraction 16) were again used as seed and incubated with 50 μM
monomeric Aβ42 for 212 hours at room temperature, followed by SEC after spinning at
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19000 x g for 20 minutes to remove fibrils. The quantitative fold increase after each
cycle was calculated by comparing the SEC profile of seeded sample with seed alone.
Generation and Isolation of Replicated LFAO (R-LFAO)
Monomeric Aβ42 (50 μM) was incubated with 5% (2.5 μM) LFAO seed in 20
mM Tris pH 8.0 at 25 C for 72 hours. After 72 hours, the sample was subjected to SEC
onto a Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes to
remove fibrils. Fractions 16 and 17 from the SEC fractionation were collected and
subjected to immunoblotting to confirm the presence of R-LFAOs.
Determination of LFAO Threshold Concentration for Self-Propagation
Monomeric Aβ42 (30 μM) was incubated alone or with 0.2, 2 and 20% (molar
ratio) LFAO seeds in 20 mM Tris pH 8.0 at 25 C for 212 hours. The aliquots of samples
were removed at 72, 144 and 212 hours and subjected to immunoblotting and SEC on a
Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes. The molar
equivalents of 0.2, 2 and 20% (molar ratio) LFAO seeds alone were also used as a
control. The quantitative fold increase after each time point was calculated by comparing
the SEC profile of seeded sample with seed alone.
Effect of Temperature on LFAO
Freshly isolated LFAOs (7 μM) was heated at varying temperatures ranging from
10-120 C for 5 minutes and allowed to equilibrate to room temperature followed by
immunoblotting and dynamic light scattering (DLS) analysis. The LFAO’s CD spectra
were also collected at 10-100 C in the far UV region with a Jasco J-815
spectropolarimeter (Jasco Inc, Easton, MD). LFAO samples were placed in a 0.1 cm
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path-length quartz cuvette (Hellma) and monitored in continuous scan mode (260-190
nm).
To study the effect of temperature on LFAO self-propagation efficiency,
monomeric Aβ42 (30 μM) was incubated alone or with 0.6 μM unheated or 80, 100, or
120 C heated LFAO seeds in 20 mM Tris pH 8.0 at 25 C for 72 hours. The supernatant
samples were then subjected to immunoblotting and SEC on a Superdex-75 HR 10/30
column after spinning at 19,000 x g for 20 minutes. The 0.6 μM LFAO seeds alone were
also used as a control. The quantitative fold increase after 72 hours was calculated by
comparing the SEC profile of seeded sample with seed alone.
Statistical Analysis
Dixon’s Q test was applied to the absorbance measurements of the R-LFAOs to
remove outliers with greater than 95% certainty. Quantitative fold increase was
calculated by dividing the absorbance of the R-LFAO’s SEC peaks by the averaged
absorbance of at least three measurements of seed alone. Levene’s test (95% certainty)
was used to test for homogeneity of variance among fold increase, and a one-way
ANOVA followed by Tukey’s HSD (Honestly Significant Difference) was used to
determine confidence intervals for each time/seed combination.
Fluorescence Spectroscopy
ThT fluorescence (F) was monitored in a microcuvette with a Cary Eclipse
fluorescence spectrometer (Varian Inc) after 15-fold dilution of Aβ42 samples into 5 mM
Tris-HCl (pH 8.0) containing 10 μM ThT. Continuous measurements of F were taken for
1 minute with the excitation and emission wavelengths fixed at 450 and 482 nm
respectively, and the excitation and emission slits set at 10 nm.
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Dynamic Light Scattering (DLS)
DLS was performed on a Zetasizer Nano S DLS instrument (Malvern Inc.,
Worcestershire, UK) in Dr. Gordon Cannon’s lab (USM). Each sample measurement
consisted of 6 runs of 10 seconds each with a pre-equilibration time of 40 seconds. After
the measurement, the number (%) was exported and plotted against size (diameter, nm)
using Origin 7.0 software.
Polyacrylamide Gel Electrophoreses (PAGE) and Immunoblotting
Samples were dissolved in loading buffer (1X Laemmli buffer) containing 1%
SDS, applied without heating to 4-12% NuPAGE gels (Invitrogen) containing bis-Tris,
and resolved in MES running buffer with 0.1% SDS. Dye-linked MW markers (Blue
Plus2 Prestained Standards, Invitrogen) were run in parallel for calibration. Gels were
electroblotted onto 0.45 m Immobilon nitrocellulose membranes (BioTraceTM NT, Life
Sciences Inc). Blots were boiled in a microwave oven in PBS for 2 minutes and were
blocked overnight with 1X PBS containing 5% nonfat dry milk and probed (1-2 hours)
with 1:1000-1:2500 dilutions of monoclonal Ab9 antibod, which detects amino acid
residues 1-16 of A . Blots were then incubated with anti-mouse horseradish peroxide
(HRP) conjugate and developed with ECL reagent (Thermo Scientific).
Atomic Force Microscopy (AFM)
AFM was done in our collaborator Dr. Sarah Morgan’s lab in the School of
Polymers and High Performance Materials at USM. Mica was cleaved using a razor
blade and taped to a magnetic sample holder. The mica stub was then covered with a 3aminopropyl-triethoxy silane (APTES) solution (500 μL APTES in 50 mL 1mM acetic
acid) for 15 minutes. The APTES solution was then decanted, and the mica was rinsed
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with 150 μL of deionized water four times. After rinsing, the mica stub was dried with
compressed N2 gas and stored in a desiccator for one hour. Next, 150 μL of 0.1-0.25 μM
A sample was added to the mica and allowed to adsorb for 20 minutes. The sample was
then decanted and the mica stub was rinsed with 150 μL of deionized water four times.
Finally, the mica stub was dried with compressed N2 gas and stored in a desiccator until
imaging. The surface topography of each sample was explored by imaging the peptide
after it had been adsorbed onto APTES treated freshly cleaved mica. These images were
obtained via an Agilent 5500 AFM (Agilent Technologies) in tapping mode, using
RTESP-etched silicon probes (length: 125 µm, nominal force constant: 40 N/m, and
resonance frequency: 275 kHz) (Veeco Instruments). While under ambient
environmental conditions, the scan rate was held constant at 1 Hz. All standard imageprocessing techniques were performed on Nanoscope version 5.30r2 image analysis
software. Nanoscope and Gwyddion version 2.7 software were used to calculate feature
heights by two methods: 1) section analysis to extract height profiles and 2) particle
analysis to determine the statistical distribution of pixel heights for individual aggregates.
Multiple areas were imaged for each sample and while height, phase and amplitude
images were collected simultaneously, only representative amplitude images are
presented.
Analytical Ultracentrifugation (AUC)
AUC was done in our collaborator Dr. Jack Correia’s lab in Department of
Biochemistry at University of Mississippi Medical Center (UMMC).
sample preparation. FITC-labeled Aβ42 (FITC-A 42) was purchased in a lyophilized
form (Bachem Inc.) and stored at – 20 C prior to use. A stock containing 5 mM FITC-
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Aβ42 in DMSO stock was prepared as described previously.41 The DMSO stock was
then diluted to 100 μM in 20 mM Tris (pH 8.0) and used for generating FITC-labeled
LFAO (FITC-LFAO). Briefly, for the generation and isolation of FITC-LFAO, 40 μM
wild type Aβ42 (WT- A 42) and 10 μM FITC- Aβ42 was mixed in 1:4 ratio and
incubated with 5 mM C12:0 fatty acid under the same conditions as described above for
LFAO preparation, and LFAOs were isolated using a similar protocol. For propagation
experiments, monomeric Aβ42 (20 μM) was incubated with 2% (0.4 μM) FITC-LFAO
seed in 20 mM Tris pH 8.0 at 25 C for 72 hours. After 72 hours, the sample was
subjected to sedimentation velocity analysis. The 0.4 μM FITC-LFAO seeds alone were
used as a control. Similarly, FITC-fibrils were prepared by mixing 45 uM WT- Aβ42
with 5 μM FITC-Aβ42 and incubated with 150 mM NaCl in 20 mM Tris pH 8.0 at 37 C
for 2-3 days. The ThT fluorescence was monitored daily until it reached a plateau. The
sample was then centrifuged at 19,000 x g for 20 minutes. The pellet was resuspended in
20 mM Tris (pH 8.0) and used for AUC analysis.
sedimentation velocity. Samples were mixed by brief vortexing and then spun in a
tabletop centrifuge for approximately 5 seconds to ensure that no sample was lost on the
walls of the tube. Samples were then loaded into 1.2 cm path length sedimentation
velocity cells (Sedvel60) and placed in an XL-A Analytical Ultracentrifuge modified to
accept a fluorescence detection system (Aviv FDS). The temperature on the centrifuge
was equilibrated until it remained constant at 20 oC for at least 5 minutes. The centrifuge
was then accelerated to 5,000 rpm, where the focus depth and gain for the fluorescence
detection system were adjusted to maximize the signal collected. The centrifuge was
then accelerated to 60,000 rpm, and data collection began immediately after final velocity
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was reached. Each scan was averaged over 5 consecutive scans to increase the signal to
noise ratio. The run was stopped when the fluorescence intensity vs. radial distance
profiles remained constant between scans, indicating that the boundary had pelleted. The
samples were then re-run for approximately 30 minutes at 60K using absorbance optics to
collect pseudo absorbance data. All data was transferred to a separate computer for
analysis; the pseudo-absorbance data was used to calculate the meniscus position for each
sample using the meniscus wizard in the software program DCDT2+ (version 2.3.2).94
The software program Sedfit (Sedfit89) was used to generate c(s) distributions for the
FDS data with 0.1 S resolution.95 The c(s) distribution for each sample was integrated
and divided by the area, and all data are presented as normalized c(s) distributions. The
software program Sedfit was also used to generate c(M) distribution after generating the
c(s) distribution by assuming a constant diffusion coefficient for all samples and an f/f o
value of 1.2. The c(M) distributions were normalized using the same methods as
described for c(s) distributions.
Circular dichroism (CD)
CD spectra were obtained in the far UV region with a Jasco J-815
spectropolarimeter (Jasco Inc, Easton, MD). Samples were placed in a 0.1 cm pathlength quartz cuvette (Hellma) and were monitored in continuous scan mode (260-190
nm). The acquisition parameters were 50 nm/min with 8 seconds response time, 1 nm
bandwidth and 0.1 nm data pitch, and data set were averaged over two scans. Spectra of
appropriate blanks were subtracted from data set as indicated. The corrected, averaged
spectra were smoothed using the ‘mean-movement’ algorithm with a convolution width
of 25 using the Jasco spectra analysis program.
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CHAPTER III
HYPOTHESIS
It is becoming increasingly evident that smaller oligomeric forms (~ 2-50mers) of
A aggregates are the primary toxic species in AD. Typically, the intermediates formed
along the pathway towards fibrils have been considered as oligomers (Figure 4).
However, it has also become evident over the years that A can adopt multiple pathways
of aggregation.41, 46, 75 More importantly, exclusive oligomers can be generated via such
alternate, ‘off-pathways’, which are distinct from the on-pathway of fibril formation.38, 41,
46, 75

As described in the previous chapter I, it is also well known that environmental

factors affect the dynamics of the on- and off-pathways of aggregation, among which
interfaces formed by lipids are significant and can promote the formation of oligomers at

Figure 4. Schematic diagram of A aggregation indicating on- and off-pathways
the cost of fibrils.96, 97 It is important to understand the pathways of A aggregation
because if some oligomers are formed as off-pathway products, their half-life could be
significantly higher than the on-pathway ones, which may result in prolonged toxicity to
neuronal cells.
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We hypothesize that alternate pathways of Aβ aggregation induced by fatty acid
interfaces can generate oligomers with unique conformations, resulting in distinct
physiochemical and cellular properties.
Specific Research Objectives
Objective 1: To study the effect of various non-esterified fatty acids (NEFAs) on A
aggregation and pathways.
We will explore whether anionic interfaces generated by these NEFAs (C9-C12)
can form off-pathway oligomers in vitro using biophysical techniques.
Objective 2: To isolate and explore the physiochemical properties off-pathway Aβ
oligomers generated in the presence of NEFAs.
We will isolate oligomers generated in the presence of NEFAs. Their
physiochemical properties will then be explored using biophysical methods and
compared with known oligomers like ADDLs, Aβ globulomers, prefibrillar oligomers
(PFOs) and fibrillar oligomers (FOs).

30

CHAPTER IV
RESULTS & DISCUSSION
The Effect of NEFAs on Aβ Aggregation
Based on the existing literature on interfacial aggregation of Aβ as described in
the previous sections, we hypothesize that NEFAs will uniquely affect Aβ aggregation in
a concentration-dependant manner.
Determination of the Critical Micelle Concentrations (CMC) of Saturated NEFAs
The CMCs of standard NEFAs are well known, but it is not a fix value and can be
greatly affected by the presence of slats and other ions in solution. In order to ensure that
the buffer and salt conditions (20 mM Tris pH 8.0 and 50 mM NaCl) used for Aβ
aggregation do not interfere with their physical properties, e.g. micelle formation,
therefore their CMC values were experimentally determined based on a previously
published report using N-phenyl-1- naphthylamine (NPN) as a fluorescent probe.98
NEFAs with varying carbon chain length of C9 (pelargonic acid), C10 (capric acid), C11
(undecylic acid) and C12 (lauric acid) were used in our study (Figure 5A). The
normalized fluorescence titration curves for varying concentrations of NEFAs are shown
in Figure 5B. The first inflection point that occurred upon increasing the fatty acid
concentration was considered to be the CMC, as reported. The CMC values determined
from Figure 5B were plotted as a function of carbon chain lengths, which showed an
expected linear relationship (Figure 5C).
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Effect of NEFAs on Aβ42 Aggregation
Previously, it has been shown that varying concentrations of SDS can affect the
rate of Aβ aggregation kinetics and can also dictate the aggregation pathway 75. Based on
this and other similar reports, Aβ42 was incubated with three specific concentrations of
NEFAs: a) below, b) near and c) above CMC.

Figure 5. Determination of Critical Micelle Concentrations (CMC). A) NEFAs
used in this study: ‘n’ represents the carbon chain length; B) N-phenyl-1naphthylamine (NPN) fluorescence response curves for various fatty acids: C9
(), C10 (), C11 () & C12 (); C) CMC of various fatty acids plotted as a
function of carbon chain length.
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Aggregation kinetics of Aβ42 co-incubated with each NEFA was monitored using
ThT fluorescence as shown in Figure 6A-D. Aβ42 peptide (25 μM), buffered in 10mM
Tris, 50 mM NaCl, pH 8.0 was incubated in the absence of NEFAs at 37 oC as a control
and showed a signature sigmoidal curve of aggregation with a lag time of ~ 58 hours
(Figure 6A-D,control).
The concentrations well below CMC for fatty acids (20 mM C9, 10 mM C10, 2
mM C11 and 2 mM C12;  in Figure 6A-D) displayed aggregation profiles similar to
that of the control. Co-incubation in the presence of NEFAs near their respective CMCs
(100 mM C9; 50 mM C10; 20 mM C11 and 5 mM C12;  in Figures 6A-D) showed an
augmented rate of aggregation based on ThT fluorescence signals, without significant
lag-times as observed in the control sample. On the contrary, Aβ incubations at
concentrations above CMC (300 mM C9, 150 mM C10, 75 mM C11 and 20 mM C12; 
in Figures 6A-D) seemed to inhibit the rate of aggregation. The data were appropriately
blank corrected.
We also removed small aliquots of samples after 130 hours of incubation from the
above reactions and subjected them to SDS-PAGE analysis and immunoblotting using
the Ab9 monoclonal antibody, which is specific to the Aβ42 N-terminus (Figure 6E).
The control Aβ42 incubated alone showed the presence of monomeric and fibrillar (F)
bands, which correlates with the observed ThT fluorescence (Figure 6E; lane 2).
Likewise, fatty acid concentrations well below CMC showed an identical banding pattern
to the control sample (Figure 6E; lanes 3, 6, 9 & 12). For near CMC fatty acid
concentrations, a predominant band around 50-80 kDa corresponding to a 12-18mer
species (lanes 4, 7, 10 & 13; indicated by triple arrows) was observed, along with
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monomeric and fibrillar (F) bands. A faint band around 20 kDa (5mers) was also
observed, indicated by double arrows (Figure 6E). On the other hand, incubations above
CMC mainly showed the presence of a 16-20 kDa band corresponding to a 4-5mer
species (lanes 5, 8, 11 & 14). In addition, a monomeric band was also observed, which
could be due to partial dissolution of aggregates by the high SDS concentration during
electrophoresis. Similarly, the appearance of the faint 20 kDa band in the case of near
CMC incubations could also be due to partial dissociation of 12-18mers.
We have termed these oligomers as ‘Large Fatty Acid-derived Oligomers
(LFAOs)’ for 12-18mers and ‘Small Fatty Acid-derived Oligomers (SFAOs)’ for 45mers, and they will be henceforth called as such. The SDS-PAGE electrophoresis
analyses were carried out on 12% bis-Tris acrylamide gels using Laemmli buffer. In
sum, it was evident from the data that concentrations near and above CMC, which
showed completely different Aβ42 aggregation patterns as compared to the control,
predominantly form two distinct oligomeric species: LFAOs and SFAOs, respectively.
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Figure 6. Dependence of Aβ42 Aggregation on Fatty Acid Concentration Monitored
by ThT Fluorescence. Monomeric Aβ42 (25 μM) was incubated at 37 C in buffer
alone () or with varying concentrations of fatty acids C9 (A), C10 (B), C11 (C) and
C12 (D), which are either above (▽), below () or around () their respective
CMCs. The data was fit with Eq 1; E) Western blots of Aβ42 with varying
concentrations of fatty acids after 128 hours of incubation probed using the Ab9
monoclonal antibody. The double arrow indicates SFAOs while the triple arrow
indicates LFAOs of A 42.
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Biophysical Differences Between LFAOs and SFAOs
Next, we studied the morphological and stability differences/similarities between
LFAOs and SFAOs using biophysical techniques.
Morphology
Atomic force microscopy (AFM) was used to observe the morphologies of Aβ42
aggregates generated in the presence of NEFAs near and above CMCs. The AFM work
was done collaboratively in Dr. Morgan’s research group at USM. Small aliquots of
sample after 240 hours of the reactions in Figure 6, both near and above CMCs of fatty
acids, were removed and deposited on a freshly cleaved mica surface, and AFM images
were taken using the tapping mode (Figure 7). As expected, the control sample in the
absence of fatty acid showed large fibrillar structures throughout the mica surface (Figure
7A). The measured averaged cross-sectional height was 6.1± 0.8nm for control fibrils,
whereas distinct morphological differences were observed between near- and aboveCMCs samples. A mixture of fibrillar and smaller rounded/oblong features were
observed for near-CMCs samples (Figure 7B, D, F, & H). The measured averaged crosssectional heights were 5.6±1.3 nm and 7.9±2.9 nm for smaller rounded/oblong and
fibrillar features, respectively. In contrast, Aβ samples incubated with NEFAs above
CMCs showed only the presence of smaller round/oblong features with a measured
averaged cross-sectional height of 6.7±1.0 nm (Figure 7C, E, G & I), and no fibrils were
present in the sample. Overall, AFM data suggest that the LFAO and fibril structures
formed in near-CMCs samples are morphologically different from SFAOs,
predominantly formed in above-CMCs samples.
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Figure 7. Morphological Differences between SFAOs and LFAOs. Aliquots of the
samples from Figure 6 were probed to see the morphologies of A 42 aggregates
generated in the presence of varying concentrations of fatty acids either near or
above CMC by atomic force microscopy (AFM). A) control; B & C) 100 & 300
mM C9; D & E) 50 & 150 mM C10; F & G) 20 & 75 mM C11; H & I) 5 & 20 mM
C12. Each square represents 5 x 5 m. The inset shows a different field with
dimensions of 1 x 1 m.
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Seeding Experiments Suggests LFAOs and SFAOs may be Structurally Different
It is evident from ThT fluorescence experiments, immunoblotting, and AFM data
that LFAOs and SFAOs may have subtle differences in their structures. As discussed
earlier, the lag-time in aggregation can be eliminated by adding preformed ‘seeds’ to
monomeric Aβ.14 The structure and morphology of the seeded aggregates depend on the
nature of seed itself. 99 This means if the added ‘seed’ has structural similarity with the
growing fibrils; the seed will promote and accelerate the formation of the ‘on-pathway’
fibrils. In previously published reports, seeding experiments were performed to
indirectly assess the structural assembly of the seed, and to understand the pathways of

Figure 8: Immunoblot of SFAOs and LFAOs. Western blots of A 42 with fatty
acids above and near the CMC, after 48 hours of incubation. The double arrow
indicates SFAOs, while the triple arrow indicates LFAOs. Monomeric A 42 and
control (in the absence of fatty acids) are represented by M and C, respectively.
aggregation.99-102 In our experiments, Aβ42 monomers were incubated with NEFAs to
generate LFAOs and SFAOs as described above. After 48 hours 10% (v/v) of the
reaction mixture was removed and added to the freshly purified, seed-free monomeric
Aβ42 at 37 C. Small aliquots of the incubated samples were electrophoresed on 12 %
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acrylamide gels to ascertain the formation of LFAOs and SFAOs after 48 hours (Figure
8A).
We also compared this to a 4-12% gradient NuPage gel (Invitrogen Inc) to get
better separation and resolution of monomeric and dimeric bands as compared to the 12%
gel (Figure 8B). No bands were observed between monomer and SFAOs for all the
samples, confirming that there were no dimer bands in the incubated samples. A positive
control sample containing Aβ42 and 2 mM SDS, which forms 2-4mers, was also included
in the gel (Figure 8B, lane 5).75
These seeding reactions were also monitored by ThT fluorescence for 100 hours
(Figure 9). The 10% (v/v) fatty acid solution was used alone as a control. The 10% (v/v)
seeds from the control Aβ42 sample alone showed marginal seeding efficiency as
indicated by a slight increase in the rate of aggregation for the seeded sample (Figure
9A). The sample containing LFAOs as seeds rapidly augmented the rate of Aβ42
aggregation as compared to unseeded control samples (Figure 9B, D, F, & H). In
contrast, the sample containing SFAOs as seed followed a similar aggregation pattern to
unseeded control samples (Figure 9C, E, G, & I).
The results indicate that LFAOs may be structurally compatible with ‘onpathway’ fibrils, thereby rapidly promoting their formation by acting as a seed, whereas
SFAOs could be structurally dissimilar to LFAOs and fibrils and therefore unable to seed
the aggregation of Aβ42. In other words, one could say that the LFAOs and SFAOs may
be subtly dissimilar in structure, which causes differences in their seeding behavior.
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Figure 9. Seeding Experiments with SFAOs and LFAOs. (A-I) A monomer (25
μM) was incubated alone or with 10% (v/v) seed of 48-hour incubated samples of
Figure 8A at 37o C and monitored by ThT fluorescence. The figures on the left and
right panel represent seeding with LFAOs and SFAOs, respectively. The unseeded
control () is same reaction as the seeded () one, except it lacks seed.
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LFAOs and SFAOs have Varying Thermodynamic Stability
Based on the seeding efficiency of LFAOs and SFAOs as observed from the
above experiment, it was evident that the oligomers may have different structural
assemblies. In order to further confirm this, differences in their equilibrium stabilities
was compared by using temporal denaturation melting curves of near- and above-CMC
fatty acids incubated with Aβ42, using GnHCl as a denaturant. In this experiment,
samples containing LFAOs and SFAOs were titrated with increasing concentration of
GnHCl and changes in intrinsic tyrosine fluorescence were monitored at 276 nm (Figure
10). No melting changes were observed upon addition of GnHCl for control monomeric
Aβ42, as expected for a natively unstructured protein (, Figure 10A, B & C). On the
other hand, LFAOs and SFAOs formed in near- and above-CMCs, respectively, showed a
significant shift in fluorescence intensity with low GnHCl concentrations followed by a
gradual decrease in intensity to almost the level of control monomeric Aβ42 with
increasing GnHCl concentrations ( & ; Figure 10). Only the melting curves for C10,
C11 & C12 were shown in Figure 10 because the first four or five data points collected
for C9 at low concentrations of GnHCl were inconsistent, especially due to high
concentration of fatty acids. It is possible that initial addition of low concentration of
GnHCl can cause precipitation of fatty acids, resulting in erratic data points followed by
stabilization of the solution at higher concentrations. Because of this, it was very hard to
collect reliable data for C9 near- and above-CMCs samples. It was observed that LFAOs
melted earlier than SFAOs in case of all three fatty acids C10, C11 & C12 (Figure 10).
The apparent melting denaturant concentration (CM) values for LFAOs (; Figure 10)
were 1.94 ± 0.05, 0.87 ± 0.1 and 1.86 ± 0.04 M for C10, C11 and C12, respectively. In
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contrast, SFAOs required a higher concentration of GnHCl for melting. The CM values for
SFAOs (; Figure 10) were 2.55 ± 0.03, 2.38 ± 0.06 and 3.83 ± 0.09 M for C10, C11 and
C12, respectively.

Figure 10. Thermodynamic Stabilities of SFAOs and LFAOs determined by
GnHCl Denaturation Experiments. A 42 (25 M) was incubated alone () or with
NEFAs C10 (A), C11 (B) and C12 (C) in similar conditions as Figure 11 at
concentrations near () and above () their CMCs. Three scans were averaged
and the areas under the peaks were normalized and plotted against GnHCl
concentrations. The data was fit using Boltzman’s sigmoidal fit (Eq. 2) by Origin
7.0. Three data sets were averaged.
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To rule out the possibility of a shielding effect by the high concentration of fatty
acids required for SFAO generation, a negative control experiment with a 7 kDa nonaggregating protein called human granulin A (Grn-A), comparable in size to Aβ42, was
performed in similar manner (data not shown). 103 The data obtained showed that there is
a slight shielding effect in higher fatty acid concentrations as compared to lower
concentrations, and this difference in melting concentrations was very low compared to
the difference between LFAOs and SFAOs. It was also interesting to observe that the
SFAOs formed in C12 fatty acid appeared to be more stable than SFAOs of C10 & C11
fatty acids. Overall, the data showed that SFAOs are more stable than LFAOs and
complement the previous data, which indicated that these two oligomeric species may be
structurally different.
Discussion
It is well known that interfaces, whether physiological or non-physiological, can
have profound effect on Aβ aggregation. The interaction of Aβ42 with medium-chain
saturated NEFAs has provided useful insights about the phenomenon of interfacial
aggregation. The data presented here clearly indicate that different concentrations of
fatty acids can dictate multiple pathways of Aβ aggregation. Interestingly, the pathway
adopted by Aβ mainly depends on the nature of interface (non-micellar/micellar)
generated by specific concentrations of NEFAs, not by the type of fatty acid used. In
other words, the same type of LFAOs or SFAOs were generated by near and above CMC
fatty acids irrespective of the carbon chain length, indicating that concentration relative to
CMC plays a crucial role in dictating pathways. This is evident from the observation that
a similar concentration of 20 mM has completely different Aβ aggregation profiles in the
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cases of C9, C11 and C12, but the Aβ:NEFA ratio was constant in all cases (Figure 6).
20 mM concentration (well below CMC) in the case of C9 does not affect aggregation,
but on the other hand the same 20 mM concentration forms LFAOs (near CMC) and
SFAOs (above CMC) in the cases of C11 and C12, respectively (Figure 6E). Moreover,
an increase in the formation of fibrils was observed at a fatty acid concentration near the
CMC, which forms LFAOs, when Aβ:NEFA ratios were increased (Figure 11).
Similarly, when Aβ:NEFA ratios for fatty acid concentrations greater than CMC, which
form SFAOs, were increased, the formation of LFAOs was observed (Figure 11),
indicating that apart from CMC, ratios of Aβ:NEFA are also crucial in dictating the
pathways and nature of oligomers formed.

Figure 11. Incubation of 5 & 20 mM C12 with Varying Concentrations of Aβ42
; lanes (1-4) 5 mM C12 with 12.5 μM , 25 μM , 50 μM , 75 μM Aβ42
respectively ; lanes (5-8) 20 mM C12 with 12.5 μM , 25 μM , 50 μM , 75 μM
Aβ42 respectively.
LFAOs and SFAOs Are Kinetically Trapped Off-pathway Intermediates
LFAOs were generated within 24-48 hours of incubation of Aβ42 with near CMC
concentration of fatty acids at 37 C and remained stable for at least 10 days. The
increased ThT fluorescence observed with LFAOs causes doubt as to whether it arises
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from LFAOs or some fibrils that may be present (Figure 7). To complicate the issue, we
know that LFAOs are structurally similar to fibrils, as they were able to seed Aβ42 fibril
formation (Figure 9).
However, two separate experiments indicated that they might be off-pathway
intermediates. First, they remained stable even after ~500 hours of incubation, which is
unlikely for on-pathway intermediates (Figure 12A). Secondly, known fibril inhibitors
like Congo Red and Rifampicin failed to inhibit the formation of LFAOs (Figure 12C). 41,
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Conversely, seeding experiments suggested that LFAOs may have structural

similarities with on-pathway fibrils because of their seeding efficiency (Figure 9), and
also NEFA free, isolated LFAOs slowly converted to fibrils after ~500 hours incubation
at 37oC (Figure 12B). Together, the data suggested that LFAOs might be kinetically
trapped as off-pathway oligomers in the presence of NEFAs, but after isolation (removal
of fatty acid, elaborated in the next section) they slowly convert into on-pathway fibrils
by associating with themselves (Figure 12). But since the conversion to fibrils of LFAOs
free of associated NEFAs occurs at a very slow rate, it is likely that LFAOs are
kinetically trapped off-pathway oligomers.
On the contrary, SFAOs formed above CMC concentration clearly indicated that
they are off-pathway species. They failed to show any increase in ThT fluorescence and
also completely failed to convert to fibrils even after ~500 hours of incubation (Figure
12C). Moreover, SFAO samples were fairly homogenous and without any fibrils as
observed by AFM images (Figure 6E and 7). And no increase in the rate of aggregation
was observed on seeding; indicating that they might be structurally incompatible with onpathway fibrils, which further complements the finding that they are off-pathway species.
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Unfortunately, all attempts to isolate SFAOs using SEC like LFAOs were unsuccessful;
therefore the seeding efficiency of isolated SFAOs was not evaluated.

Figure 12. Oligomeric LFAOs as well as SFAOs are Formed Along ‘Off-pathway’.
All samples were electrophoresed on 4-12 % NuPage gels with MES running buffer.
A) Immunoblots of incubations of buffered 25 μM Aβ42 with 5 and 20 mM C12 for
~500 hours at 37 C similar to Figure 11. Double and triple arrowheads indicate
SFAOs and LFAOs respectively; B) Immunoblots of SEC fractionated LFAOs (9
μM) of Aβ42 (Figure 20) in 20 mM Tris-HCl, 50 mM NaCl, pH 8.0 incubated at
37 C for the indicated times; C) Effect of fibril inhibitors like Congo red (CR) &
Rifampicin (Rfn) on Aβ42 oligomer formation. Lanes 1-5 show 25 μM Aβ42
incubations with 5 mM C12: lane 1 – with no inhibitors, lane 2 and 3 – with 6- and 8fold molar excess of CR, lane 4 and 5 – with 6- and 8-fold molar excess of Rfn.
Lanes 6-10 show similar 25 μM Aβ42 incubations with 20 mM C12: lane 6 – with no
inhibitors, lane 7 and 8 – with 6- and 8-fold molar excess of CR, lane 9 and 10 – with
6- and 8-fold molar excess of Rfn.
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Together, the data suggested that both LFAOs and SFAOs are transiently trapped
as off-pathway oligomers. It is also possible that fatty acid might play an important role
in stabilizing the structure of oligomers, and their removal may have a destabilizing effect
on oligomers.
The exact nature of the Aβ-NEFA interaction is unclear at this time. However, a
rough model portraying the possible mechanisms of Aβ-NEFA interaction based on the
above results is shown in Figure 13. If non-micelle

micelle was assumed to be a

determined reaction with the equilibrium constant, KD, being equal to the CMC value,
then it is obvious that above the CMCs, Aβ mainly interacts with the micellar form
(Figure 13). Based on our observation of SFAO formation, it seems likely that the
anionic interface provided by micelles accommodates 4-5 Aβ monomers. These SFAOs
seem to be thermodynamically more stable (stabilized by micelles) than LFAOs (Figure
10). Interestingly, no effect on Aβ aggregation was shown with non-micellar
concentrations of NEFA (<<CMC) (Figure 6). Near the CMC concentration, a dynamic
equilibrium exists between non-micellar

micelle transitions, which seems to exert a

unique effect on Aβ aggregation. Near CMC, no well-defined interface forms, this may
result in different modes of interaction between Aβ and fatty acids (Figure 13). In other
words, LFAOs may be kinetically trapped intermediates along the ‘off-pathway’ as
compared to thermodynamically stable SFAOs.
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Figure 13. Schematic Model of Aβ42 Aggregation Pathways in the Presence of NEFAs
Based on the Data Obtained in the Study. The square brackets indicate isolated
oligomers while the question marks indicate that these parts were not explored in this
study.
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Physiochemical Properties and Self-propagation of LFAOs
LFAOs and SFAOs generated in the presence of 5 and 20 mM C12 fatty acid
respectively were isolated using SEC to further explore their stability in the absence of
fatty acid, physiochemical properties and prion-type self propagation behavior.
Isolation of Oligomeric LFAOs and SFAOs
In order to further characterize these oligomeric species, it was very important to
isolate them, free of monomers, fibrils and fatty acids. This will help in understanding
and exploring the molecular features of these specific oligomeric species and provide
information about their stability in the absence of fatty acids. To do so, 50 μM Aβ42 was
incubated with 5 or 20 mM C12 fatty acid for 48 hours to generate LFAOs and SFAOs
respectively, as shown in Figure 6E (Chapter IV.1). After 48 hours, LFAOs (incubation
with 5 mM C12) were subjected to SEC using a Superdex-75 column (see next
subsection VII). The presence of residual NEFAs present, if any, in the isolated LFAO
fractions was quantified using a free fatty acid assay kit (BioVision Inc., Milpitas,CA)
method as published previously.104 This experiment indicated a negligible amount
(<0.1%) of NEFA was present in fractions containing isolated LFAOs (Figure 14). The
results clearly suggest that LFAOs can maintain their structural integrity even after
isolation and removal of fatty acids. Attempts to isolate SFAOs using SEC were
unsuccessful (data not shown) and hence, were not further pursued.
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Figure 14. Quantitation of NEFA Content in Isolated LFAOs: The amount of
NEFA associated with LFAOs before and after SEC fractionation was estimated
using free fatty acid quantification kit. The experiment was performed as per the
manufacturer’s instructions. Briefly, a standard curve was generated by adding 2 μl
aliquots of a known concentration of palmitic acid to each well containing the
reaction mixture provided by manufacturer (). The reactions were monitored
colorimetrically at 570 nm. The concentration of NEFA present in 2 μl aliquots of
LFAOs before (pre SEC; ▲) and after (post SEC; ●) isolation by SEC were
estimated using standard curve. Based on this analysis, NEFA concentration before
SEC was estimated to be 4.5 mM, which is comparable to the 5 mM used. On the
other hand, for the isolated LFAO, a negligible amount of NEFA was detectable in
the sample, suggesting a complete removal of NEFAs from LFAOs upon
fractionation.
LFAOs are Disperse Oligomers
The isolation of LFAOs generated in the presence of 5 mM C12 and their
molecular size distribution were estimated using SEC and analytical ultracentrifugation
(AUC), respectively. The Aβ42 was incubated with 5 mM C12 fatty acid at 37 C for 48
hours to generate LFAOs as described (Figure 6E; Chapter IV.1) and subjected to
fractionation on a Superdex-75 SEC column (Figure 15A, smooth line). The samples
eluted in two major peaks, one between fractions 17 and 20 and the other between
fractions 22 and 25. A small extra peak was also observed near the void volume (fraction
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16) of the column. The LFAOs are eluted in the partially included volume fractions 17
and 18 as compared to monomers, which eluted in fractions 22-25. The SEC profile of
LFAOs was compared with those of globular protein standards (gel filtration standards,
Bio-Rad) to estimate the molecular mass of LFAOs based on retention volume (data not
shown). Based on this analysis, the molecular mass of LFAOs was estimated to be
between 60 and 200 kDa. Additionally, Aβ42 protofibrils (PFs), which have a molecular
mass >200 kDa were also subjected to fractionation under similar condition as LFAOs. 105,
106

The SEC profile of PF sample mainly showed two elution peaks, one at the void

volume at fraction 15 (Vo; Figure 15A, black arrow) for PFs and second for monomers at
fractions 22-25 (Figure 15A, dashed line). The SEC fractionation of PFs further
supplemented our observation with globular protein standards that molecular mass of
LFAOs is between 60 and 200 kDa. The AFM of the isolated LFAOs mainly showed a
bimodal distribution of non-fibrillar punctuate dots like structures with an average height
ranging from 7-10 and 16-19 nm (Figure 15A, inset).
The sedimentation velocity experiments in an analytical ultracentrifuge were
performed to estimate the molecular size distribution of LFAOs. The AUC experiments
were done in our collaborators Dr. John Correia lab at UMMC. For these experiments,
FITC-Aβ42 was introduced into LFAOs assembly (as described in the Materials and
Methods, Chapter II) to facilitate monitoring by fluorescence detection system (FDS).
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Figure 15. Isolation and Characterization of LFAOs. A) The SEC fractionation of
LFAOs using a Superdex-75 column in 20 mM Tris pH 8.0 at room temperature with a
flow rate of 0.5 mL/min and a fraction size of 0.5 mL. As a comparison, a sample of
protofibrils (PFs) of Aβ42 was as also fractionated. Vo indicates the void volume
based on globular protein standards. (Inset): AFM image of fractionated LFAOs.
Scale bar represents 2.5 μm. B) Normalized c(S) distribution profile generated from a
sedimentation velocity experiment performed at 50,000 x g. (Inset): Immunoblot of
LFAOs before and after fractionation. Single arrow indicates 50-70 kDa bands while
double arrow indicates 80-110 kDa bands.
In AUC, the rate of sedimentation of macromolecules was monitored in the
presence of centrifugal force, which allows the determination of their hydrodynamic
radius and thermodynamic properties in solutions.107 AUC is the method of choice to
determine the exact molecular mass of proteins and their complexes and also to study
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protein self-assembly and heterogeneous interactions like protein-protein, protein-DNA
and protein-small agents.107
Labeling with FITC reduces the amount of sample needed and facilitates
detection at very low concentrations. The c(S) sedimentation coefficient distribution
profile, which helps to model the hydrodynamic radii of proteins and their complexes in
solution, of LFAOs before and after fractionation was analyzed to observe any size
differences (Figure 15B). The Aβ42 sample incubated with 5 mM C12 before
fractionation when subjected to AUC showed a distribution of multiple peaks with a
sharp peak centered on 4 S and a more disperse peak between 6 and 12 S with a
additional peak at ~ 1 S (Figure 15B, dotted lines). The 1 S peak corresponds to
monomeric Aβ42 as determined by running a control sample (Figure 16A), and SEC
fractionated LFAOs (fraction 17) showed an almost identical AUC profile as the
unfractionated sample, with a main peak centered at 5 S and a second disperse peak
between 7 S and 12 S, along with a monomeric 1 S peak (Figure 15B, smooth lines). The
LFAOs showed a similar peak distribution even after 10- & 50-fold dilutions (data not
shown). A relative decrease in the amount of monomers was also observed after SEC:
52.3% and 14.3% monomers before and after fractionation, respectively. The Aβ42
fibrils were also analyzed by AUC to compare with LFAOs; they on the contrary showed
a heterogeneous mixture of large species between 40 and 200 S (Figure 16B). The
immunoblots of the LFAO sample both before and after SEC primarily showed a disperse
band between 56 and 110 kDa with two distinct band distributions; one is around 56-70
kDa and other is centered at 80-110 kDa (Figure 15B, inset). The immunoblot band
distribution further complements the bimodal distribution observed in AFM and AUC
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data. Together, the data suggest that LFAOs are not discrete, but a disperse mixture of
oligomeric species.
LFAOs are Self-propagating Oligomers
Prion proteins are well known to undergo corruptive template assisted self
replication by converting normal prion proteins (PrPC ) to misfolded (PrPSc)form.77
Recent studies have shown that a prion-type propagation mechanism is also involved in
the pathogenesis of other neurodegenerative diseases like PD, FTLD and ALS.80-84 But
prion type self-propagation is a relatively new and unexplored area in the AD field, and
so far only two oligomeric species of Aβ, prefibrillar (PFOs) and fibrillar oligomers
(FOs), have been shown to possess a self-propagating property upon interaction with
monomeric Aβ.85, 86 Therefore, we want to explore whether LFAOs can self-propagate
upon monomer addition.

Figure 16. AUC of Monomer and Fibril. A c(S) distribution profile generated from
sedimentation velocity experiments for Aβ42 monomers (A) and fibrils (B).
For this experiment, 20 μM freshly purified, aggregate-free, monomeric Aβ42
was incubated with 0.4 μM (2% molar ratio) isolated LFAOs as a seed at ambient
temperature, and the reaction’s progression was monitored with ThT, immunoblotting
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and SEC. Small aliquots of samples were removed at 24, 48 & 72 hours and subjected to
SDS-PAGE and immunoblotting. The amount of sample loaded in each lane was kept
constant at 28 ng based on the initial concentration of LFAOs seed (Figure 17A), for the
approximate quantification of the blots. The immunoblot clearly showed a more intense
LFAO band centered around 100 kDa within 24 hours compared to the 0 hour sample
(lane 3). The 100 kDa band represents the higher molecular weight species of LFAO
(80-110 kDa) from the two species observed for isolated LFAOs (lane C), and the lower
molecular weight species (~56-70 kDa) was completely absent (Figure 17A; 24 hours).
A progressive increase in the 100 kDa band intensity was observed after 48 and 72 hours,
along with a continuous decrease in the monomer band intensity, indicating that
monomers were being converted into more LFAOs (Figure 17A; 48 and 72 hours).
Moreover, a large molecular weight species was also observed at the top of gel after 72
hours (lane T; 72 h), which was absent in the supernatant sample loaded on the gel after
centrifuging the sample for 20 minutes at 19,000 x g, suggesting the formation of fibrils.
Some degree of fibril formation was expected because it is likely that besides monomerLFAO interactions, monomer-monomer interactions occur in parallel, leading to onpathway fibrils. The propagation reaction was also monitored by ThT fluorescence
(Figure 17C). The Aβ42 seeded with 2% LFAOs (Figure 17C,○) showed a lag phase of
~72 hours as compared to control ~84 hours (Figure 17C, ■), indicating a relatively
insignificant amount of seeding. But a significant amount of seeding (reduction in lag
phase) was observed with 20% seed in our previous experiment (data not shown). A
significant amount of LFAOs was also observed in the seeded sample immunoblots run
during the lag phase (24, 48 and 72 hours), which was not seen in the control (Figure
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17A). This clearly suggests that the propagation of LFAOs mainly occurred during the
lag phase. Notably, immunoblots showed that the propagation reaction occurring upon
seeding with LFAOs only leads to the formation of 80-110 kDa oligomeric species at the
expense of the 56-70 kDa species observed in LFAO seeds.
In order to confirm that propagation leads to a quantitative increase in LFAOs that
would occur in a self-propagating event, SEC was used. Aβ42 (50 μM) was seeded with
2% LFAOs (1 μM) and incubated for 72 hours. Immunoblots after 24, 48 and 72 hours
of incubation confirmed propagation process as shown in Figure 17A. The samples were
subjected to SEC fractionation after the indicated times. Fractions 16-19 showed the
presence of propagated LFAOs on immunoblots (Figure 17B). A ~4-fold increase in the
amount of LFAOs was observed in SEC, as shown by absorbance in comparison with
non-seeded sample fractions after 72 hours (Figure 17D). The Far-UV CD of SEC
fraction 17 at 24, 48 and 72 hours points also showed a progressive increase in β-sheet
conformation, further complementing the observation of an increase in LFAO amount
upon seeding (Figure 17E). The formation of 80-110 kDa species upon seeding that
seemed to occur at the cost of 56-70 kDa species was confirmed by sedimentation
velocity analysis before and after 72 hours of propagation cycle at room temperature
(Figure 17F). The sample after propagation showed a significant peak shift towards ~80110 kDa species (Figure 17F, smooth line), which supported the immunoblot data (Figure
17A) and consolidated the observation that the high molecular weight ~80-110 KDa
species was predominantly formed upon propagation. A slight decrease in the amount of
monomer ~6 % was also observed in the seeded sample AUC data (Figure 17F), further
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strengthening the observation that propagation leads to quantitative conversion of
monomer to LFAOs.

Figure 17. LFAOs Propagate upon Interacting with Monomers. A) Immunoblot of 20 μM
Aβ42 incubated with 0.4 μM LFAO (2 % seed) for 72 hours at room temperature before and
after SEC. C represents LFAO control (338 ng). Lanes 1 and 2 are Aβ42 control after 72
hours in the absence of LFAO seed and LFAO alone (28 ng), respectively. Lane 3 is an
aliquot of 20 μM Aβ42 seeded with 0.4 μM LFAO immediately after incubation (0 h).
Lanes T and S represent the total and supernatant of the sample after centrifugation at
19,000 x g for 20 min, at the indicated times of incubation. The volume of sample loaded
was kept constant to ensure 28 ng of the parent LFAO was maintained. B) Immunoblot of
fraction 17, fractionated by SEC after 24, 48 & 72 hours of incubation of the samples in A
(lanes S). C) ThT fluorescence data of the seeded reaction. The arrow indicates the 72 hour
point to which the seeding reaction was monitored. D) Fraction 17 of the seeded samples,
which was fractioned on a Superdex-75 column after 24, 48 & 72 hours along with a control
sample (no seed) after 72 hours. E) The corresponding far-UV CD spectra of fraction 17,
and F) Normalized relative molecular weight distributions, c(M) profiles obtained from
sedimentation velocity data for control LFAOs (dotted line) and seeded oligomers (smooth
line). (Inset) Expanded region of the c(M) plot indicated in the figure.
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Morphology of propagating LFAOs
The morphology of the seeded sample was also monitored using AFM at different
time points to observe any changes that might occur during propagation (Figure 18). The
0 hour sample, i.e. immediately after seeding (Figure 18A & D), showed few spherical,
small, punctate dots ~8 nm in heights, representing LFAOs. The 48 hour (Figure 18B &
E) sample showed a considerable increase in the number of spherical LFAOs along with
a slight increase in height (~12 nm), and they appear to align in a straight linear line
(inset). The sample after 72 hours (Figure 18C & F) showed a further increase in the
number of spherical dots with similar height profiles (~14 nm), along with a linear
alignment of the particles (inset) and a few smooth fibrillar structures. More importantly,
the linear alignment of these spherical particles gives the overall appearance of
‘maturing’ PF. A similar type of linear arrangement was observed previously when Aβ40
was incubated in the presence of aqueous-organic interface.93 Furthermore, AFM data
complements the immunoblotting and AUC data and suggests that LFAO undergoes
propagation.
Incorporation of Monomers into Replicated LFAOs
N-terminal Dansyl labeled Aβ42 (Dan-Aβ42) was used as a fluorescent probe to
further ensure that seeding leads to incorporation of monomers into replicated LFAOs
assembly.
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Figure 18. Morphological Changes during LFAO Propagation. Aliquots of the samples
from Figure 17A (before SEC) were probed at different time points to see the
propagation of oligomers after incubating 20 μM Aβ42 with 0.4 μM LFAO (2 % seed)
for 72 hours at room temperature. A, B & C, represent AFM images of the seeded
sample after 0, 48 & 72 hours, respectively (z scale, 0-0.8 V). D, E, and F represent the
corresponding height data from A, B & C, respectively (z scale, 0-40 nm). The white
scale bar represents 2.5 μm, and the inset shows a field of dimensions 1 x 1 μm
surrounding the particles indicated with arrows. The white boxes in D-F indicate the
particles for which the height analyses were conducted. Height profiles were extracted
from the flattened height data and can be seen from the z direction in the height images
and from the x, y direction below each image. These height profiles demonstrate how
approximate feature heights were determined for each sample. The determined feature
heights were confirmed via particle analysis (Nanoscope version 5.30 r2 image analysis
software), shown at the bottom as a secondary technique to increase confidence in
reported values.
A schematic of the reaction of Dan-Aβ42 and LFAOs is shown in Figure 19A,
indicating that seeding with LFAO should generate replicated oligomers containing
labeled peptides, which can be easily detected by intrinsic fluorescence. A seeding
experiment similar to Figure 17A was performed using 50 μM Dan-Aβ42 and 1 μM
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LFAOs for 72 hours at room temperature. After 72 hours, the seeded sample was
centrifuged at 19,000 x g to remove any fibrils, and the supernatant was subjected to SEC
fractionation and immunoblotting (Figure 19B & C). The SEC profile for the isolation of
propagated LFAOs was exactly comparable to the isolation profile in Figure 17D. The
immunoblot also clearly showed a significant increase in the amount of LFAOs after 72
hours as compared to 0 hour (Figure 19C, lanes 4, 5, & 6). The SEC fractionated sample
(fractions 17 & 18) also showed the presence of replicated LFAOs in immunoblot (Figure
19C, lanes 8 & 9), whereas monomers were fractionated in the inclusion volume peak at
fraction 24 (Figure 19C, lanes 10). The fluorescence spectra of fractions 17 & 18 were
collected by exciting the sample at 350 nm while monitoring Dan-Aβ42 emission at 450
nm (Figure 19D). Importantly, both fractions showed dansyl emission at 450 nm,
indicating that Dan-Aβ42 monomers were incorporated into the propagated LFAO
assembly upon seeding, providing an unambiguous confirmation for the replication
mechanism. In sum, the collective data suggest that LFAOs are self-propagating strains
of Aβ oligomers.
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Figure 19. Incorporation of Dan-Aβ42 Monomer into Replicated Oligomers after
Seeding. A) Schematic for incorporation of Dan-Aβ42 into propagated LFAOs after
seeding for 72 hours. B) 20 μM Dan-Aβ42 incubated with 0.4 μM LFAO (2% seed)
for 72 hours at room temperature. The seeded sample was fractioned on a Superdex75 SEC after 72 hours; Inset – immunoblot showing the comparison of seeded
sample before and after SEC. C represents control LFAO (338 ng). Lane 1 shows
Dan-Aβ42 control after 72 hours. Lane 2 shows an aliquot of the sample after 0 hour
(total). Lane 3 shows the incubation after 72 hours. Lanes 4 and 5 show fractionated
samples, fractions 17 & 18, respectively, after 72 hours. C) Fractionated sample,
fractions 17 & 18 showing the Dan-Aβ42 emission at 450 nm upon exciting at 350
nm with a band width of 20 nm (10/10).
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LFAOs Form Non-fibrillar, Diffuse Aggregates in Aqueous-Organic Phase Interfaces
buffer-hexane and buffer-chloroform experiments. Interfaces are well known to affect Aβ
aggregation, especially aqueous-organic phases.47 It has been recently shown that
prefibrillar oligomers (PFOs) form distinct pore like structures called annular protofibrils
(APFs) upon interaction with water-hexane interfaces, which remain stable for long
periods of time without forming fibrils.47 It is believed that the formation of this

Figure 20. LFAO Agitation in Interfacial Environments. A) The increase in size of
LFAO after agitation with 5% (v/v) hexane or chloroform in buffer followed by
dialysis for 23 hours was monitored by DLS. B) Immunoblot of the agitation
experiments along with monomer controls. Lane 1 shows control monomer Aβ42;
lanes 2 and 3 dialyzed 23 hours Aβ42 monomer sample treated with chloroform &
hexane, respectively. Lane 4 shows control LFAO; lanes 5 and 6, dialyzed 23 hour
Aβ42 sample treated with chloroform & hexane, respectively. The single and double
arrows indicate 50-70- and 80-110-kDa bands, respectively.
ring/pore like structures is one of the mechanisms by which oligomers exert their toxicity.
The effect of aqueous-organic phase interfaces on LFAOs was explored to observe
whether they could form any non-fibrillar off-pathway aggregates like APFs. Two
interfacial systems were used for these experiments: hexane-water (as used previously for
PFOs) and chloroform-water. For this experiment, a protocol previously published for
PFOs was followed, and based on that protocol, freshly isolated 2 μM LFAOs were
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mixed and agitated with 5% (v/v) hexane-water on a vortexer for 1 hour.47 After
agitation, the sample was dialyzed at room temperature for 23 hours, followed by DLS
analysis of the dialyzed sample. The LFAOs treated in hexane-water prominently
exhibited the formation of large species with a hydrodynamic radius of ~700 nm (Figure
20A, gray peak), whereas LFAOs in buffer alone showed a monodisperse peak with a
~10 nm diameter (Figure 20A, black peak) correlating well with the AFM data (Figure
15A, inset), which showed an average height range of 7-10 nm. But an immunoblot of
the same sample failed to show any large species; instead an unexpected decrease in the
band intensity was observed (Figure 20B, lane 6). Interestingly, upon the same
treatment, Aβ42 monomer showed a high molecular weight species band that failed to
enter the gel, indicating the formation of fibrils (Figure 20B, lane 3).
The same experiment was repeated with the chloroform-water system, to see
whether it was possible to replicate the formation of larger aggregates in other interfaces
too. The main advantage of using chloroform as compared to hexane is that it is denser
than water, and buffers can be easily suspended at the top of the organic layer. The 2 μM
LFAOs were mixed, agitated and dialyzed in a similar manner as with hexane and
monitored by DLS, which showed a polydisperse distribution of species with two peaks:
~700 and 1000 nm (Figure 20A, light gray peak). The immunoblot of the dialyzed
sample showed a significant shift towards a higher molecular weight band, further
complementing the DLS data (Figure 20B, lane 5). In contrast, upon the same treatment,
Aβ42 monomer again showed the formation of a very large molecular weight species that
failed to enter the gel (Figure 20B, lane 2).
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morphology of the aggregates formed after chloroform and hexane treatment. The AFM
image of the LFAO treated with hexane-water interface showed the presence of very
large spheroidal aggregates with an average height of ~33 nm (Figure 21 A). The
spheroidal aggregates were almost 3-4 times larger than individual LFAOs in apparent
diameter and are believed to result from association of LFAOs (Figure 21A). In contrast,
Aβ42 monomer treated with hexane showed the presence of fibrillar structures (Figure
21B). It is important to point out that LFAOs do not form any ring- or pore-like structure
like PFOs on hexane treatment, indicating that the assembly of different soluble
oligomers can vary depending upon their molecular organization. 47 LFAOs treated with
chloroform also showed the presence of large aggregates with an average height of ~21
nm (Figure 21C). More importantly, Aβ42 monomer treated with chloroform does not
show any large fibrillar structures (Figure 21D), as expected based on the immunoblot
data that clearly indicate the presence of a high molecular weight band at the top of the
gel (Figure 20B, lane 3). It is possible that dilution during AFM sample preparation
might have caused the disaggregation of unstable aggregates formed in chloroform
interfaces. This observation was similar to the report published previously for Aβ40, in
which unstable aggregates get completely disaggregated upon dilution.52 Collectively,
DLS and AFM data indicate that LFAOs, upon treatment with interfaces, also form large,
non-fibrillar, disperse aggregates with completely different morphology from PFOs and
that these aggregates may not be the intermediates of the fibril formation on-pathway.
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Figure 21. Morphology of Aggregates Formed after Treatment with Chloroform and
Hexane. A & B) AFM images of LFAO and monomer Aβ42 control, respectively,
agitated with hexane. A) LFAOs show the presence of small globular aggregates and
large clumps of aggregates. B) Control monomers treated with hexane show the
presence of fibrils. C & D) AFM images of LFAO and monomer Aβ42 control,
respectively, agitated with chloroform. C) LFAOs show the presence of several large
clumps of aggregates. D) Control monomers treated with chloroform failed to show the
presence of any aggregates. The height images are presented here. The white scale bar
represents 2.5 μm, and the inset shows a field of dimensions 1 x 1 μm surrounding the
particles indicated in the box. The z scale for all the images is 0-40 nm. These height
profiles demonstrate how approximate feature heights were determined for each sample.
The determined feature heights were confirmed via particle analysis (Nanoscope version
5.30 r2 image analysis software) shown at the bottom as a secondary technique to
increase confidence in reported values.
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Discussion
The physiochemical properties of LFAOs that were characterized in this section
indicate that they are diffuse oligomeric species with a molecular mass ranging from ~56110 kDa. More importantly, immunoblots of isolated LFAOs showed two prominent
band distributions: a lower molecular weight species band ranging from ~56-70 kDa and
a high molecular weight species band from ~ 80-110 kDa, corresponding to 12-15mers
and 18-24mers respectively. AUC sedimentation velocity data complemented the
observation that LFAOs are a mixture of oligomeric species, with a heterogeneous peak
distribution of species corresponding to 5 S, and 7-12 S sedimentation coefficients. A
somewhat similar AUC sedimentation velocity profile was recently published by Freir
and coworkers for ADDLs, indicating that they are also a heterogeneous mixture of
oligomeric species larger than 90 kDa with a very disperse c(S) distribution ranging from
10 S to 25 S.108
The most significant and novel property of LFAOs is their self-propagation
behavior, which can help discover new insights into the pathogenesis of AD. The LFAOs
can act as seeds to convert non-toxic monomers into toxic, non-fibrillar aggregates,
displaying a mechanism similar to the ‘template-assisted corruptive’ self-propagation of
prion proteins (Figure 22A).77, 109, 110, 111 It is also possible that the self-propagation of
LFAOs can act as a trap to direct more monomers away from the fibril formation onpathway to a more toxic off-pathway. Furthermore, propagation leads to a quantitative
increase in the amounts of LFAOs formed. The key practical utility of this property is
that it could be exploited to enhance the amount of endogenous oligomeric seeds by
amplification to an extent amenable for biophysical characterization, following a method
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similar to the ‘Protein Misfolding Cyclic Amplification (PMCA)’ method reported
previously by Soto and co-workers for in vitro prion protein amplification (discussed in
the next section).78, 112
LFAO: A Novel Off-pathway Self-propagating Intermediate
All the data presented so far further support our proposed hypothesis that
oligomers need not be formed along the mandatory fibril formation pathway. LFAOs and
some other oligomers, like PFOs and FOs, share a common trait in that all of them
nucleate the formation of oligomers from monomers but not fibrils.47, 86, 113 Furthermore,
the formation of non-fibrillar aggregates upon interactions with monomers and also on
LFAOs association suggest that the LFAOs are off-pathway intermediates that can also
compete and recruit more monomers towards this toxic pathway through a unique
replication mechanism (Figure 22B). More importantly, the association property of
LFAOs upon their interfacial interaction can provide valuable insights about the
mechanism and behavior of endogenous LMW oligomers in the presence of lipid
interfaces in the physiological environment. Figure 22B also illustrates the possibility of
energy minimum states along the aggregation pathway, and it is likely that oligomers get
trapped in these kinetic minima and thereby promote prolonged toxicity. Therefore, it is
possible that these off-pathway routes can recruit more monomers to populate LMW
oligomers and are more toxic than the nucleation dependent on-pathway.
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Figure 22: Schematic Diagram Depicting the Generation of ‘Off-pathway’
Oligomers and Propagation. A) The classical fibril formation ‘on-pathway’ of Aβ
aggregation along with an ‘off-pathway’ is depicted. The process of replication of
off-pathway oligomers is shown with dotted lines. B) An aggregation funnel is
similar to the protein folding funnel but depicts the aggregation of intrinsically
disordered proteins such as Aβ towards fibril formation. This path is considered the
nucleation-dependant ‘on-pathway’. The spherical balls represent LMW oligomers.
However, it is possible that the oligomers adopt a different pathway such that they
are trapped in local energy minima as ‘off-pathway’ species (oval ball; grey area of
the funnel). Such off-pathway species would have a significant energy barrier to
overcome in order to proceed towards fibrils. Also, the off-pathway oligomers could
recruit more monomers and dictate them to adopt such pathways (replication
process). This may further increase the energy barrier for such off-pathway
oligomers to overcome and significantly increase their half-lives in doing so.
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Evaluation of Prion-type Behavior of LFAOs
Encouraged by the prion-like template assisted self-propagation mechanism
displayed by LFAOs as described in the previous chapter, we wanted to further explore
whether LFAOs are indeed ‘Prions’.112, 114 The scrapie form of prion, PrPSc (misfolded
prion protein), is known to undergo a ‘protein misfolding cyclic amplification’ (PMCA)
process in which small amounts of PrPSc seeds can be amplified upon making them
interact with the folded, non-toxic form (PrPc) of the protein under controlled conditions
in vitro.112, 114 Such in vitro amplified prions are reported to retain the infectious
properties of their in vivo counterparts.115 The utility of PMCA is that the assay can be
used as a diagnostic tool for detecting the presence of pathogenic prions by amplifying
extremely low amounts of in vivo PrPSc seeds. The amplification of seeds by the in vitro
PMCA assay is greatly influenced by the parameters like buffer, temperature, pH,
sonication and time of incubation etc.112, 114 Therefore, for LFAO self propagation,
optimization of some these crucial parameters is essential to see how, if at all, they can
affect the propagation efficiency of LFAOs.
Cyclic Propagation of LFAOs
In order to assess whether LFAOs could undergo PMCA-type amplification as
reported for prions, the PMCA protocol developed by Soto and colleagues was followed
for the amplification of LFAOs, with some modifications.114-116 It is interesting to point
out that LFAOs showed self-propagation behavior at an ambient temperature without
requiring any special sonication conditions, which is critical for in vitro prion
amplification.112, 114
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First, as described in the previous section, LFAOs were subjected to selfpropagation by seeding (2%) 50 μM buffered Aβ42 monomers at room temperature for
72 hours. After 72 hours, the incubated sample was centrifuged at 19,000 x g for 20 min
to remove any fibrils, and the supernatant was subjected to fractionation by SEC using a
Superdex-75 column (Figure 23A). This amplification/propagation cycle of LFAO was
termed as ‘Cycle-1’. The comparison of SEC profiles of the seed alone (dotted line) and
seeded sample (black line) are shown in Figure 23A. The seeded sample showed a ~3.5
fold increase in the amount of seeds after Cycle-1 as compared to seed alone (Figure
23D; Cycle-1), consistent with our previous observation (Chapter IV.2). The
immunoblot of the aliquots of seeded sample (Figure 23 E; Cycle-1, lanes T&S) after 72
hours prior to SEC also showed a similar increase in the amount of LFAOs compared to
seed alone (Figure 23 E; lane seed). More importantly, the seeded sample (Figure 23E;
Cycle-1, lanes T&S) showed a replicated LFAO (R-LFAO) band centered around ~100
kDa after Cycle-1, which was also consistent with our previous observation that
replication led to the formation of higher molecular weight species of LFAO (~80-110
kDa) (Chapter IV.2; Figure 17).113 SEC fractions 16 and 17 (Figure 23 E; Cycle-1, lanes
1&2) also showed the presence of isolated R-LFAOs. Moreover, a high molecular
weight band, which failed to enter the gel and was likely fibrils, was also observed after
72 hours in seeded samples (Figure 23 E; Cycle-1, lane T).
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Figure 23. Cyclic Propagation of LFAOs. A, B & C show LFAO propagation cycles
after 72, 96 and 212 hours, respectively, monitored by SEC fractionation on a Superdex
75 column. The SEC profile comparison of seeded sample (solid line) with seed alone
(dotted line) was shown to indicate the quantitative increase in the amount of LFAOs
after each cycle. D) The quantitative estimate of LFAOs’ fold increase after each cycle
was calculated by comparing the SEC peaks of seeded with seed alone. E) Immunoblot
of LFAO samples after each amplification cycle. Lane seed shows the LFAO used as
seed for cycle 1. Lane C shows an Aβ42 control without any seeds for each cycle at
indicated time points. Lanes T & S show the total and supernatant of the seeded sample
after centrifugation at 19,000 x g to remove any fibrils after each amplification cycle.
Lanes 1 & 2 shows replicated LFAOs in SEC fractions 16 & 17 after Cycle-1.
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The fibril band was absent in the supernatant (Figure 23E; Cycle-1, lane S),
further confirming that these bands were indeed fibrils. The presence of some fibrils is
expected due to on-pathway fibril formation reactions (monomer-monomer interactions)
that occur simultaneously to monomer-LFAO interactions. For the second propagation
cycle (Cycle-2), the SEC fractionated R-LFAOs from Cycle-1 (fraction 16, lane 1; Figure
23 E) were used as seeds (50% v/v) to 50 μM Aβ42 monomers at room temperature for
96 hours (Figure 23 B). A 50% v/v was used for seeding in Cycle-2 because the precise
concentration of isolated R-LFAOs was difficult to calculate due to dilution. After
several screens, we increased the incubation time from 72 to 96 hours for Cycle-2,
because the amount of seeds used were approximately 2/3 less than in Cycle-1. After 96
h, the supernatant of the seeded sample was subjected to SEC fractionation, and fractions
16 and 17 were collected and compared to the seed alone (Figure 23 B; Cycle-2). The
seeded sample in Cycle-2 showed a ~2.3 fold increase after 96 hours (Figure 23D; Cycle2). Interestingly, the seed alone showed a faint R-LFAO band centered around ~ 100
kDa (Figure 23 E; Cycle-2, lane S), but fractionation did not lead to detectable amounts
on immunoblot (data not shown). The amplification cycle was further continued using
fraction 16 of Cycle-2 as seed (50% v/v), but the incubation time was increased to 212
hours in order to be able detect the replicated oligomers. No amplicafication was
observed even after 212 hours (Figure 23 D; Cycle-3). As expected, the corresponding
immunoblot did not show the presence of any R-LFAOs (Figure 23 E; Cycle-3, lane S).
Based on the SEC profiles, the concentrations of seed used in Cycles -2 & -3 were
approximately estimated to be around 0.29 μM (0.59%) and 0.025 μM (0.05%)
respectively (data not shown).
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The data clearly indicates that LFAOs undergo significant amplification after
Cycle-1, but amplification efficiency decreases by ~35% after Cycle-2 and becomes
insignificant after Cycle-3. There could be two possible reasons for this behavior: a) RLFAOs are less efficient in amplification because of their larger size as compared to
original LFAOs (~100 kDa versus 56-80 kDa for LFAOs and R-LFAOs respectively). A
similar observation was reported for PrPSc protein by Castilla et al., in which they showed
that larger aggregates of PrPSc formed above 100 °C are less efficient for amplification as
compared to parent PrPSc.115 b) The amount of seeds used in Cycle-3 is well below the
threshold concentration of seed (minimum amount required to self-propagate).101, 117
Comparison of Seeding Efficiency of R-LFAOs vs. Parent LFAOs
First we wanted to analyze the effect of size difference between LFAOs and RLFAOs on self-propagation. Cycle-2 of LFAO amplification, in which R-LFAO, the
larger oligomeric band (~80-110 kDa) of native LFAOs, was used as a seed, showed less
efficient propagation as compared to Cycle-1, which used parent LFAOs (~56-80 kDa).
The R-LFAOs were generated as previously described (see Materials & Methods). In
order to see whether larger aggregates are less efficient in promoting amplification, the
same LFAO propagation procedure was repeated using 2% of SEC isolated R-LFAOs as
seed for 20 μM buffered Aβ42 monomer. The same percentage of original LFAO seed
was also used as a control for the comparison of propagation efficiency with R-LFAOs.
After 96 hours, both samples were subjected to immunoblotting and SEC. Additionally,
to keep the conditions of the amplification cycle constant, samples were incubated for 96
hours instead of 72 hours. In Figure 24 (inset), lanes 2 and 4 show the control and RLFAOs samples after 96 hours respectively. The immunoblot band intensity for both the
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samples was identical. However, quantitative SEC comparison showed a ~2.4 and ~1.6
fold increase for the control and R-LFAO seeded sample, respectively (Figure 24). More
interestingly, R-LFAOs showed a ~33 % decrease in amplification efficiency as
compared to control, which is identical (~35 %) to the decrease observed after Cycle-2 of
LFAO amplification (Figure 32). The data clearly indicates that larger ~80-110 kDa RLFAOs are less efficient in amplification as compared to native LFAOs, further
complementing our previous observation.
Physiochemical Differences and Similarities between LFAOs and Prions
effect of temperature on LFAO propagation and other physiochemical properties.
Previous studies on PrPSc protein replication and propagation have shown that high
temperatures can promote the formation of larger aggregates, which can greatly reduce
the amplification efficiency.115 To investigate whether LFAOs showed a similar
property, the effect of temperature on LFAO propagation was explored. A 7 μM
incubation of LFAOs was heated for 5 min at specific temperatures ranging between 10
and 120 oC and subjected to DLS analysis. Small aliquots of these samples were then
subjected to immunoblotting (Figure 25A). A significant shift towards higher molecular
weight was observed for samples heated at 80, 100 and 120 °C (Figure 25A, lanes 2, 3, &
4) as compared to control unheated LFAOs (Figure 25A, lane 1). The 100 and 120 °C
samples showed a large disperse band ranging from 80 to >260 kDa.
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Figure 24. Comparison of Propagation Efficiency of Parent LFAO vs. R-LFAO.
20 μM Aβ42 was incubated with 2% (molar ratio) parent LFAO (black bar) and
replicated LFAO (R-LFAO, grey bar) at room temperature for 96 hours. After 96
hours both the samples were subjected to SEC and quantitative fold increase was
calculated by comparing the SEC profiles. The inset shows an immunoblot of
LFAO and R-LFAO seeded sample after 96 hours. Lanes 1 & 2 shows parent
LFAO seed alone and 96 hour seeded sample, respectively. Lanes 3 & 4 shows RLFAO seed alone and 96 hours seeded sample, respectively.
A similar shift towards larger size was also observed for 80, 100 and 120 °C
samples in DLS (Figure 25 B). The heat-treated LFAO samples at 80 (dark grey), 100
(grey) and 120 °C (light grey) showed monodisperse peaks centered at ~11 , ~18 and ~
37 nm in diameter, respectively, all of which were larger in diameter than the unheated
LFAO sample (black peak; ~7 nm in diameter) (Figure 25B). It is evident that an
increase in temperature promotes larger aggregates of LFAOs. The treatment of LFAOs
at lower temperatures (20-60 oC) did not cause any changes compared to the unheated
LFAO sample in either DLS or immunoblots (data not shown). The CD analysis showed

75

an increase in β-sheet content, characterized by a minimum at 216 nm, with increasing
temperature (Figure 25 C). This observation was consistent with the report by Gursky
and colleagues, who showed that heating Aβ40 at higher temperatures caused an increase
in β-sheet content, suggesting further oligomerization and aggregation.118 Similar reports
have also been reported for other amyloidogenic proteins.119
Next, we compared the seeding and propagation efficiency of 80, 100, and 120 °C
heated LFAO sample with unheated LFAO sample. For seeding and propagation, 20 μM
freshly purified, seed-free Aβ42 was incubated at room temperature for 72 hours either
with 0.4 μM (2% molar ratio) unheated LFAO as a control or with LFAOs that had
previously been heated to 80, 100 or 120 °C. Immunoblot lanes 2, 4, 6, and 8 show the
comparison of propagation efficiency between unheated and 80 and 100 °C heated LFAO
samples (Figure 25 D). The quantitative fold increase, determined by comparing the SEC
peaks of seeded sample and seed alone, and indicated a ~2.5 fold increase for the
unheated LFAO sample (Figure 25E, unheated). In contrast, the 80, 100 and 120 °C
heated LFAO samples showed 1.4, 0.7 and 0.4 fold increases respectively (Figure 25 E;
80, 100, & 120 °C), indicating a decrease in amplification/propagation efficiency with the
increase in temperature. A statistical analysis of variance (ANOVA) on the data
indicated >90% (Figure 25 E, 80 °C; ●) and >99% (Figure 25 E, 100 & 120 °C; **)
significance in the difference between the seeding efficiency of unheated LFAO and 80,
100 and 120 °C heated LFAO after 72 hours.
The data also suggest that, although they do so with diminished efficiency, even
the larger aggregates of LFAO were able to undergo self-propagation, as no fibrils were
observed. This clearly demonstrates that the entire propagation process occurred along
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the off-pathway, as we had hypothesized (see chapter IV.2.). The data further indicates
that higher temperatures can induce the formation of larger aggregates and reduce the
amplification efficiency, a behavior similar to PrPSc propagation.115
determination of LFAOs’ threshold seed concentration and seeding efficiency. A
minimum critical concentration of seeds is required for the initiation of polymerization in
nucleation-dependent aggregation reactions.101, 117 In order to determine the threshold
seed concentration for LFAOs to undergo self-propagation, 30 μM buffered Aβ42 was
incubated with 0.2, 2, and 20% (molar ratio) LFAO seed at room temperature for 212
hours. Small aliquots of samples were removed at 72, 144 and 212 hours and subjected
to SEC and immunoblotting to observe the quantitative increases in the amount of
LFAOs (Figure 26).
Immunoblot lanes 1, 2, and 3 show 0.2, 2, and 20% LFAO seed alone,
respectively (Figure 26 A), and lanes 4, 5, and 6 show 0.2, 2, and 20% LFAO seeded
sample after 212 hours, respectively (Figure 26 A). A significant increase in the amount
of LFAOs was observed in the immunoblot for the 0.2% seeded sample (Figure 26 A,
lane 4), as compared to the seed alone (Figure 26 A, lane 2), which was undetectable
after 212 hours. The quantitative increase in LFAOs after each time point was calculated
by comparing SEC peaks of seeded sample versus seed alone (Figure 26 C). Figure 26 B
represents the SEC profiles of 0.2 (continuous line), 2 (dotted line), and 20% (dashed
line) seeded samples after 212 hours respectively.
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Figure 25. Effect of Temperature on LFAOs. A) Immunoblot showing LFAOs
heated at different temperatures. Lane 1 shows unheated LFAO sample as a control.
Lanes 2, 3, & 4 show LFAOs heated at 80, 100 and 120 °C, respectively. The
increase in LFAO size after heating is shown by double arrows. B) DLS analysis of
LFAOs heated at different temperatures. C) CD spectral analysis of LFAOs heated
at different temperatures. D) Immunoblot showing a comparison of propagation
efficiency of unheated vs. 80, 100 & 120 °C LFAOs after 72 hours. Lanes 1 and 2
show unheated LFAO seed alone and seeded sample, respectively. Lanes 3, 5 & 7
represent 80, 100 & 120 °C heated 0.4 μM (2% molar ratio) LFAO seed alone,
respectively, while lanes 4, 6 & 8 represent 20 μM Aβ42 incubated with 0.4 μM (2%
molar ratio) 80, 100 & 120 °C heated LFAO seeds, respectively. E) Determination
of LFAOs’ quantitative fold increase, determined by comparing the SEC profiles of
the unheated, 80, 100 and 120 °C heated LFAO seeded samples with seed alone; ●
and ** represent 90 and >99.9% significance, determined via ANOVA.
The reaction seeded with 0.2% LFAOs showed a ~6 fold increase as compared to
~2 fold increases by 2 and 20% seeded reactions after 212 hours (Figure 26 C). The
0.2% sample also showed a significant increase in LFAOs after 72 and 144 hours, but the
maximum efficiency was observed only after 212 hours (Figure 26 C). Statistical
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analysis on the data indicated >99.9% (Figure 26 C; ***) confidence in the increase of
LFAO amount for 0.2% as compared to 2 and 20% after 212 hours. All attempts to
detect LFAOs in 0.02% (molar ratio) seeded samples by SEC and immunoblots were
unsuccessful (data not shown); indicating that this seed concentration was below the
threshold of optimal seeding efficiency.
Collectively, the data show that 0.2% (molar ratio) LFAO is the most efficient
seed concentration for promoting propagation to an exceptionally significant limit,
allowing for easy detection by SEC and immunoblots. Furthermore, the data indicate that
the threshold seed concentration of LFAOs required to initiate propagation for 30 μM
Aβ42 is ~0.06 μM (270 ng/mL), below which replication is experimentally undetectable.
The data further explain our observation that Cycle-3 of the LFAO
propagation/amplification (Figure 23 C), which was initiated by 0.025 μM seed,
completely failed to show any propagation, as the LFAO concentration was below the
threshold concentration determined here (0.06 μM).
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Figure 26. Determination of LFAOs’ Threshold Seed Concentration and Seeding
Efficiency. A) Immunoblot of 30 μM Aβ42 seeded with 0.2, 2, and 20% (molar
ratio) LFAO seeds after 212 hours. Lane C shows control Aβ42 incubated alone
after 212 hours. Lanes 2, 3, and 4 represent 0.2, 2, and 20% (molar ratio) LFAO
seeds alone, respectively. Lanes 4, 5, and 6 represent 0.2, 2, and 20% (molar ratio)
LFAO seeded sample after 212 hours, respectively. Single and double arrows
indicates original LFAO seeds at ~56-70 kDa and R-LFAO bands at ~80-110 kDa
after propagation, respectively. B) SEC profile of 0.2, 2, and 20% (molar ratio)
LFAO seeded sample after 212 hours. C) Determination of LFAOs’ quantitative
fold increase at different time points, by comparing the SEC peak profiles of the 0.2,
2, and 20% (molar ratio) LFAO seeded sample with seed alone; ●, *, **, and ***
represents 90, >95, >99 and >99.9% significance based on analysis of variance using
ANOVA.
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Discussion
In prion diseases, self propagation of the misfolded PrPSc form by a ‘templateassisted corruptive’ mechanism is a well known phenomenon.77 Many recent studies on
prions have shown that it is possible to replicate the in vivo infectious mechanism under
in vitro conditions using the PMCA method.112, 114, 116 In PMCA, a small amount of
endogenous PrPSc seed can be amplified with complete structural faithfulness upon
addition to native PrP using successive cycles of sonication and incubation to an amount
easily detectable for diagnostic purposes.112, 115
In the AD field, prion type propagation is an emerging hypothesis, and recent in
vivo studies have demonstrated this phenomenon in transgenic mouse models.88
Recently, Stόhr and coworkers have shown that synthetic Aβ can act as prions and
undergo self-propagation and migration upon inoculation into mouse brains.89 In the
previous results section (Chapter IV.2.), we have shown that LFAOs can also selfpropagate by converting monomers into more LFAOs at the expense of fibrils, displaying
a behavior similar to prions, which forms the first such in vitro observation.113
Similarity between LFAO and Prion Propagation
In this section, we have presented the similarities and dissimilarities between
prion and LFAOs propagation. A method similar to PMCA was used for LFAO
propagation and indicated that small amounts of LFAOs, upon monomer addition,
undergo significant amplification/propagation like prions during Cycle-1, but
amplification/propagation efficiency decrease by ~32% for Cycle-2, due to the formation
of R-LFAOs. Propagation becomes insignificant after Cycle-3. Interestingly, the RLFAOs, when used as a seeds for the propagation experiment also showed a ~32 %
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decrease in amplification efficiency as compared original LFAO seed, clearly indicating
that the higher molecular band of LFAOs is less efficient in promoting propagation.
Interestingly, LFAOs, when subjected to higher temperatures, showed the formation of
larger aggregates, which are less efficient in promoting amplification when used as a
seed, a behavior similar to prions.115 More importantly, data clearly indicated a similarity
in the propagation behavior of LFAOs and prions in in vitro. LFAO propagation has an
advantage in that it is very straight forward, not requiring optimization of any special
parameters as in the PMCA method of prion amplification.
LFAO Threshold Seed Concentration
We could not detect any amplification of LFAOs after Cycle-3, which could be
due to the seed amount being well below the threshold concentration necessary to initiate
such a process.101, 117 Seed concentrations below 0.2% failed to show any propagation
efficiency and were completely undetectable under experimental conditions. Based on
this analysis, the LFAO threshold seeding concentration was determined to be ~60 nM
for 30 μM Aβ42 , which is 2.5 times less than the ~150 nM required to initiate in vitro
propagation of prions.117
Significance
These findings are significant as they are the first comprehensive demonstration
of in vitro prion type propagation of Aβ oligomers. So far, LFAOs are the only
biophysically characterized in vitro oligomers that act as ‘prions’. This Aβ prion
propagation has immense practical implications and can be utilized to amplify small
amounts of endogenous seed to amounts feasible for biophysical and structural
characterization using exogenous monomers. The early detection of similar, self-
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propagating oligomeric species, having similar conformation as LFAOs, in plasma and
CSF could be used as a potential biomarker for diagnostic purposes in AD. Future
studies will be directed towards elucidating LFAOs prion type propagation behavior in in
vivo conditions.
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CHAPTER V
CONCLUSIONS AND FUTURE WORK
Conclusion-1: All Oligomeric Species Need not Be Formed along the
Obligatory On-pathway: Physiological Significance
LMW oligomers are believed to be the primary toxic species involved in the
etiology of AD. As a result of their increased significance in AD pathology and lack of
structural information about these oligomers, many research groups have shifted their
primary focus to the identification and characterization of both in vivo and in vitro Aβ
oligomers. This focused approach towards oligomers resulted in several new important
findings. So far, it has been believed that oligomers are formed as transient intermediates
during the fibril formation on-pathway. However, the observation of polymorphism
among Aβ aggregates indicated the possibility of multiple Aβ aggregation pathways.
Only a few observations have been reported indicating that Aβ oligomers may formed
along an alternate pathway completely different from classical nucleation-dependent onpathway. 41, 46, 75, 96, 120
The significance of understanding multiple pathways lies in the fact that if some
oligomers are formed along the off-pathway, they might have a longer self half-life
compared to the on-pathway species, resulting in prolonged toxicity to neuronal cells.
The data presented here further strengthen the multiple pathways hypotheses and indicate
that both CMC as well as Aβ:fatty acid/lipid ratios play significant roles in dictating the
pathway of Aβ aggregation and forming off-pathway oligomers (Chapter IV.1).
Interestingly, these off-pathway oligomers seem to possess unique physiochemical
properties compared to their on-pathway counterparts.
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The Aβ peptide is amphipathic in nature, as result of which it has high affinity for
membranes, which have in turn also been shown to affect the early stages of Aβ
aggregation.69-71, 121, 122 GM-1 gangliosides containing lipid rafts as well anionic
phospholipids have also been shown to increase the rate of Aβ aggregation.72, 123-126
Apart from lipids, oligomers generated by fatty acids like lauric acid, oleic acid and
arachidonic acids were shown to inhibit hippocampal LTP in Tg2576 mice model.37
Interestingly, other amyloidogenic proteins like α-synuclein, apolipoprotein C-II and
prions have also been shown to display unique behavior in the presence of various
interfaces.127-130 Recently, it was shown that the misfolded, infectious PrPSc form of prion
protein obtained from the conversion of normal, bacterially expressed, recombinant prion
protein undergoes propagation only after interacting with a membrane anionic
phosphatidyl surface.131 All of the observations and data presented here clearly indicate
the physiological significance of lipid- and fatty acid-induced interfacial aggregation of
Aβ, which could generate structurally and biologically unique oligomers that may be
important in the AD pathology.
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Conclusion -2: Prion Type Self-propagation: A Unique Property
of ‘Off-pathway’ Oligomers
The prion-type corruptive template-assisted mechanism of infectivity is a newly
emerging hypothesis among neurodegenerative diseases. Recent studies and finding have
shown that synthetic as well as brain-derived Aβ can undergo prion type propagation and
promote acceleration of disease in mouse models.88, 89, 132 However, none of the reports
demonstrate the molecular aspects of Aβ displaying prion characteristics. Previous
studies have shown that in vitro Aβ oligomers like PFOs and FOs can display prion type
behavior, but one important drawback of all these oligomers is that they are not
biophysically well characterized, which is a limiting factor for understanding the details
of the mechanism.85, 86 One of the most significant findings of our studies is that we have
shown that a unique, off-pathway, in vitro oligomer called LFAO, generated in the
presence of fatty acid interfaces and biophysically well characterized, can undergo priontype self propagation, quantitatively converting more monomers into toxic oligomers at
the expense of fibrils.113 Moreover, LFAOs can undergo similar in vitro amplification as
has been shown for prions using the PMCA method.112, 114 All these data and previous
findings clearly indicate a common link between AD and prion toxicity mechanisms,
which may be the underlying mechanism among many neurodegenerative disorders.
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Future Work
Future studies will be directed towards elucidating the structure of LFAOs using
biophysical techniques like Fourier transform infrared (FTIR) spectroscopy, mass
spectrometry etc., which will provide a better understanding of their propagation
mechanisms and help to further explore the similarities/dissimilarities between LFAOs
and other known in vitro oligomers, on-pathway intermediates and fibrils.
The efficiency of LFAOs to cross seed and propagate other proteins will also be
explored using similar experimental methodology as used for LFAO propagations. These
proteins will include mutant forms of Aβ42 as well as both wild type and mutant forms of
Aβ40 involved in both AD and cerebral amyloid angiopathy (CAA). In addition, cross
seeding with Parkinson’s-associated α-synuclein will be also investigated. This study
will help to explore whether all these neurodegenerative disorders are interconnected and
whether one can increase the chance of occurrence or severity for others.
Finally, toxicity of LFAOs will be explored on human neuroblastoma cells using
the XTT reduction assay. Furthermore, we will also explore the effect of LFAOs on NFкB activation, which is involved in A -induced endothelial adhesion and transmigration.
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